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Recent advances in vaccine development include the incorporation of novel adjuvants to 
increase vaccine immunogenicity and efficacy. Pattern recognition receptor (PRR) ligands 
are of particular interest as vaccine adjuvants. During early childhood, the B cell 
compartment contains a high frequency of immature, transitional B cells. This prominent 
transitional B cell population may encounter PRR ligands during immunization; however, the 
response of human transitional B cells to these stimuli remains largely unknown. The goal 
of this dissertation work was to evaluate the capacity of PRR ligands to drive transitional B 
cells to mature into follicular or marginal zone B cells by assessing transitional B cell 
maturation and evaluating the transcriptome of mature B cell subsets. This work determined 
that PRR ligands can drive the phenotypic maturation of human transitional B cells as 
measured by CD23 expression and Rhodamine 123 retention. In vitro transitional B cell 
maturation resulted in the generation of both Fo-like and MZ-like B cells as determined by 
surface phenotype. Additionally, select PRR ligands induced gene expression changes in 
transitional B cells similar to mature B cells.  We analyzed human tonsil follicular and 
marginal zone-like B cell transcriptomes to identify several genes uniquely associated with 
either cell fate decision and assessed the expression of some of these genes in our in vitro 
transitional B cell maturation model. To the best of our knowledge, this is the first study to 
examine the differential effect of various PRR ligands on the maturation of human 
transitional B cells into mature, naïve B cells and to examine the follicular versus marginal 
zone B cell fate decision. The rational design of vaccine adjuvants that take into 
consideration the effect of PRR ligands on B cell maturation and differentiation may lead to 
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While vaccines are considered to be one of the most effective methods to control 
communicable diseases, there are no approved vaccines for many infectious diseases 
including malaria, HIV, dengue and West Nile virus. Candidate vaccines for malaria and 
dengue have provided promising results in Phase III clinical trials. The most advanced 
subunit malaria vaccine candidate with moderate effectiveness, RTS,S/AS01, is being 
assessed in several large-scale pilot implementations in sub-Saharan Africa (1). A 
recently published study analyzed the immunogenicity of the vaccine to assess its rate 
of waning (2). Differences in vaccine efficacy were age- and exposure-dependent, with 
anti-circumsporozoite antibodies waning rapidly in the first 6 months followed by slower 
waning over the next 4 years. Therefore, improved efficacy and long-term memory 
induction are still needed to make it a successful public health tool. One of the potential 
approaches to improve subunit vaccine efficacy and durability is through the use of 
adjuvants. While RTS,S/AS01 contains a liposome-based adjuvant system (AS01), 
other adjuvant systems may yield more efficacious and long lasting responses.  
There are a variety of possible adjuvants in development, however, much of the 
rationale for choosing an adjuvant is empirical, rather than mechanistic (3). The metrics 
for assessing a “good” adjuvant are safety, tolerability, ability to increase vaccine 
potency, reduce the required antigen dose, and induce long lasting immune response 
(4). To date, there are a handful of adjuvant formulations licensed for use in human 
vaccines, of which only four are licensed for use in the US, including aluminum salts. 
The lack of safe and effective adjuvants is widely acknowledged as a major obstacle in 
modern vaccine development.  
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Background 
Pattern recognition receptors in innate and adaptive immunity 
First-generation vaccines, including inactivated/attenuated viruses or bacteria, contain 
inherent adjuvants that aid in immune responses to a particular pathogen. These 
adjuvants include pathogen components in the form of viral RNA, DNA, surface 
glycoproteins, lipopolysaccharides, etc. Next-generation vaccines build on the 
knowledge that adjuvants in vaccine formulations can differentially trigger the innate 
immune system and downstream signaling leading to a controlled adaptive immune 
response. Therefore, synthetic molecules are being designed to resemble pathogen-
associate molecular patterns (PAMPs) that interact with pattern recognition receptors 
(PRRs), one of the main mechanisms of innate immune activation. PAMPs in clinical 
and experimental use as candidate vaccine adjuvants are small, immunostimulatory 
molecules that target cell membrane or cytosolic PRRs (5). PRRs include Toll-like 
receptors (TLRs), Nod-like receptors (NLRs), C-type lectin receptors (CLRs), and RIG-I-
like receptors (RLRs), with expression varying on different cell types (6). TLRs are the 
most well-studied and well-characterized PRRs. There are 10 TLRs now described in 
humans, with TLR1, 2, 4-6 found on the cell membrane and TLR 3, 7-9 found on 
endosomal membranes. TLRs recognize a variety of bacterial and viral components: 
lipopeptides (TLR1/2/6), double-stranded RNA (TLR3), lipopolysaccharides (TLR4), 
flagellin (TLR5), single-stranded RNA (TLR7/8), and unmethylated CpG motifs (TLR9). 
NLRs are a family of 22 cytoplasmic receptors (7), of which NOD1, NOD2, and NLRP3 
are the most well-studied. NOD1 and NOD2 recognize diaminopimelic acid (DAP)- 
containing muropeptides and muramyl dipeptide (MDP) groups, respectively, found 
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commonly on the cell wall of gram-negative bacteria (8). NLRP3 responds to a wide 
variety of compounds including uric acid crystals and chitosan and participates in the 
NLRP3 inflammasome complex (8). CLRs are expressed on the cell surface and 
recognize carbohydrate chains predominantly found on mycobacterial and fungal 
organsims (9, 10). Downstream signaling of PRR activation include pro-inflammatory 
cytokine secretion and chemokine expression, driving the generation of antigen depots, 
enhancement of antigen presentation, and upregulation of activation markers on antigen 
presenting cells (3).  
 
The PRR ligands of interest to our lab and their receptors include: Polyinosine-
polycytidylic acid (Poly (I:C), TLR3), Glucopyranosyl lipid adjuvant (GLA, TLR4), 
Imidazoquinoline (R848, TLR7/8), γ-D-Glu-mDAP (iE-DAP, Nod1), CpG ODN 2006 
(CpG, TLR9), and trehalose-6,6-dibehenate (TDB, C-type lectin receptor Mincle) (Table 
1). These PRRs are expressed on different immune cells in differing frequencies. The 
ability of PRR ligands to trigger a variety of cell types involved in an effective immune 
response makes them good vaccine adjuvant candidates.  
 



























































































































































































































































































































































































































































Human B cell populations 
Germinal center formation is key to the production of high affinity antibodies and B cell 
memory (11), two critical elements of immunity to many viral, bacterial, and protozoan 
pathogens, including malaria. Transitional, marginal zone (MZ), and follicular (Fo) B 
cells contribute to the development, structure, and function of germinal centers (12). 
Transitional B cells are recent emigrants of the bone marrow. These cells have 
successfully passed central tolerance in the bone marrow and express a properly 
formed B cell receptor, however, they are still considered immature. Three stages of 
transitional B cells have been identified in the human based on cell surface markers: T1, 
T2, and T3, of which T1 B cells are the most immature. Transitional B cells are highly 
susceptible to BCR-induced apoptosis and exhibit poor ex vivo survival due to their 
functional immaturity (13). Upon maturation in the periphery, transitional B cells 
differentiate into MZ or Fo B cells localized to secondary lymphoid organs. The exact 
mechanism and timing of B cell fate decisions is not completely understood, however, 
the role of BCR signal strength and Notch signaling have been suggested (14). It is 
commonly proposed that a strong BCR signal supports Fo B cells while a weak BCR 
signal favors MZ B cells. Additionally, the Notch2 signaling pathway participates in MZ B 
cell commitment. The spleen is the only secondary lymphoid organ with a true marginal 
zone, although marginal zone-like regions have been identified in Peyer’s patches and 
tonsils. In the spleen, MZ B cells border the perifollicular zone and due to their close 
proximity to peripheral circulation act as a first line of defense to blood borne pathogens. 
MZ B cells are constantly in a pre-activated state allowing their rapid differentiation into 
IgM-secreting plasma cells in response to BCR crosslinking. MZ B cells can also bind 
 7 
and shuttle antigen into the B cell follicle (15). The majority of transitional B cells, 
however, mature into Fo B cells, responsible for T-dependent antigen responses and 
differentiation into memory B cells or plasma cells. In addition, MZ and Fo B cells have 
been implicated in the differentiation and maintenance of T follicular helper (Tfh) cells 
(16), the limiting factor in the maturation of high affinity B cells.  
 
MZ B cell controversy 
Recent literature has demonstrated that human MZ B cells have variable surface 
marker expression and tissue distribution. It is therefore recognized that the human MZ 
B cell population is heterogeneous but shares three common characteristics: 1) the 
ability to recirculate, 2) CD27 expression, and 3) the presence of mutated VDJ genes 
(17-19). Since these three characteristics are hallmarks of memory B cells, there has 
been a debate over whether MZ B cells are a subset of memory B cells or represent an 
independent B cell lineage. One hypothesis states that MZ B cells are a distinct 
subpopulation that arise in a germinal center-independent manner (20-22). The 
alternative hypothesis states that MZ B cells are post-germinal center memory cells that 
have retained IgM expression, rather than switching to another immunoglobulin isotype 
(22). Most literature identifies human MZ B cells as IgM+ IgD+ CD27+, referring to these 
cells as IgM memory B cells. Evidence for both hypotheses will be discussed. 
 
Several immunodeficiencies including hyper-IgM syndrome, X-linked lymphoproliferative 
syndrome, and common variable immune deficiency result in absent or aborted GC 
formation (23-25). In these patients, although GCs are absent and/or aborted, IgM+ IgD+ 
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CD27+ MZ B cells are still found. This supports the hypothesis that MZ B cells can form 
in a GC-independent manner. Additionally, antigen-specific IgM memory B cells can 
form in response to T-dependent antigens in mouse models where GC formation is 
prevented, including Bcl-6-deficient bone marrow (26) and CD28-/- mice (27). Although 
the mutation frequency of these B cells is lower in these mice as compared to wild type, 
their presence indicates that GCs are not necessary for MZ B cell development.  
 
A number of other studies provide evidence in support of the alternative hypothesis that 
MZ B cells are post-GC memory cells. Somatic hypermutation (SHM) occurs prior to 
isotype switching in GCs (28), therefore, it is possible that abortive GCs can give rise to 
IgM+ memory B cells. Additionally, most IgM+ CD27+ B cells have undergone less 
proliferation than switched memory B cells (29), which is indicative of an early exit from 
the GC, as seen in abortive GC formation.  
 
To refute the theory that abortive GCs may give rise to mutated MZ B cells, studies 
have shown that MZ B cells undergo SHM during the generation of the pre-immune 
repertoire, supporting the hypothesis that MZ B cells are a distinct subpopulation that 
develops in a GC-independent manner (30). The expression of activation-induced 
cytidine deaminase (AID), an enzyme required for the induction of SHM, has been 
observed in immature murine B cells with somatically mutated Ig V genes (31). In 
immature B cells, SHM is necessary for the removal and tolerization of autoreactive B 
cells prior to GC entry (32). These studies suggest that B cells can undergo SHM 
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outside of GCs. Since B cells in the marginal zones contain little to no AID, these cells 
must have undergone SHM prior to entering the MZ (33).  
 
IgM+ CD27+ MZ B cells are critical for responses to T-cell independent (TI) antigens. 
Asplenic children and adults have low frequencies of IgM+ CD27+ MZ B cells, which 
correlates with increased frequency of encapsulated bacterial infections. However, 
switched memory B cells are also found at a lower frequency in asplenic children and 
adults. Therefore, the response to TI antigens may be contributed from both IgM+ 
CD27+ MZ and switched memory B cells. If IgM+ CD27+ MZ B cells are a distinct 
subpopulation critical for TI antigens, this population should be enriched for clones 
specific for bacterial polysaccharide TI antigens. Tsuiji et al. (34) showed that less than 
4% of IgM+ CD27+ MZ B cells are polyreactive to TI bacterial antigens as compared to 
more than 10% of mature naïve B cells. Additionally, IgM+ CD27+ MZ B cells have been 
shown to efficiently respond to T-cell dependent antigens. Together, these data suggest 
that IgM+ CD27+ MZ B cells are not the only subpopulation critical for TI responses. 
 
Aranburu et al. (35) studied paired peripheral blood and splenic samples from children 
of different ages to understand how age- and tissue-specific events shape the memory 
B cell compartment including IgM+ CD27+ MZ B cells. They proposed that, in addition to 
switched memory B cells, three types of IgM memory B cells exist: innate IgM memory 
B cells, remodeled IgM memory B cells, and GC-derived IgM memory B cells. Innate 
IgM memory B cell development is GC-independent, spleen-dependent and found 
primarily in infants. They have a low mutation frequency and their immunoglobulin 
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repertoire is quasi-germline. If the individual has a spleen, innate IgM memory B cells 
have the potential to undergo somatic hypermutation in a GC-dependent manner to 
become remodeled IgM memory B cells. Remodeled IgM memory B cells are found in 
older children. The third type of IgM memory B cell is GC-derived IgM memory B cells. 
Found in both infants and older children, GC-derived IgM memory B cells do not require 
the spleen but do require GCs and IL21 for SHM to occur. In comparison to innate IgM 
memory B cells, GC-derived IgM memory B cells have restricted Ig repertoires. The 
finding of three types of IgM memory B cells indicates that the MZ may change with age 
consisting of innate IgM memory B cells at infancy and GC-experienced IgM memory B 
cells during adulthood. 
 
PRR expression on human B cell populations 
PRR ligands can trigger the activation and differentiation of a variety of cells. Of 
particular interest to an effective immune response is the activation and differentiation of 
B cell subsets important to functional germinal centers. PRRs are expressed on human 
B cell subsets, however, information on PRR expression is limited as most analyses are 
done with the B cell population as a whole (9, 36, 37) which is not a homogenous 
population. Often B cells from peripheral blood are analyzed because of accessibility. 
Unfortunately, the major B cell populations involved in antigen processing, presentation 
and proper germinal center formation are localized to the draining lymphoid tissues. 
Additionally, PRR expression is known to alter in response to various stimuli, such as 
BCR and/or CD40 ligation. For example, resting naïve B cells have relatively low TLR 
expression, however, in response to BCR ligation several TLRs are upregulated (38). 
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The variability between B cell subsets and differences in activation states complicates 
much of the PRR expression data. Table 2 is a summary of select PRRs and their 
expression on various human B cell subsets.  
 
Table 2. Pattern recognition receptor expression on human B cell subsets. 
















TLR 1 + ++ + ++
TLR 2 +/- - + +
TLR 3 - - - -
TLR 4 +/- - - +/-
TLR 5 +/- - + -
TLR 6 ++ ++ + ++
TLR 7 ++ ++ + +
TLR 8 +/- + - -
TLR 9 + [23, 24] + ++ + +
TLR 10 + ++ + +
NOD1 + (tonsil B cells) [17]
+ (tonsil B 
cells) [17] ++
NOD2 - (tonsil B cells) [17]







































PRR role in B cell maturation and activation 
Several studies have implicated a role for PRR signaling in B cell maturation. TLR9 
ligation of human transitional B cells has been shown to drive terminal differentiation to 
a marginal zone phenotype and secretion of IgM antibodies (39, 40). Others have 
demonstrated the role of TLR signaling in germinal center regulation (41). Various 
studies have shown that mouse and human B cells increase co-stimulatory molecule 
expression, secrete IgM antibodies, and proliferate in response to different PRR ligands 
(39, 42-45).  
 
Incorporation of adjuvant alters the immune response 
Adjuvant-specific immune responses are being extensively studied (6, 46-48). Knudsen 
et al. performed a comparative analysis of five clinical-grade adjuvants (Alum, MF59, 
GLA-SE, IC31, CAF01) with three model antigens from M. tuberculosis, influenza, and 
Chlamydia (46). This analysis allowed the direct comparison of each adjuvant’s immune 
profile in human PBMCs and the immune profile changes depending on the antigen. 
Emulsion-based adjuvants like Alum and MF59 favor Th2 responses, while adjuvants 
that contain PRR agonists (CAF01 – Mincle agonist, IC31 – TLR9 agonist) favor Th1 
responses. GLA-SE is an interesting adjuvant because of the balanced Th1/Th2 profile 
it elicits in mice. GLA (glycopyranosyl lipid adjuvant) is a TLR4 agonist that alone 
induces a polarized Th1 response in mice. However, when GLA is formulated with SE 
(a stable emulsion of oil-in-water), a potent Th1 response is balanced with enhanced 
antibody titers (49). With a better understanding of adjuvant mechanisms of action and 
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their resulting immune signatures, we can design vaccines using a mechanistic 
rationale. 
 
Malaria vaccines and their adjuvants – efficacy and responses 
Over the past 30 years, more than 25 different malarial antigens in formulation with 
more than 15 different adjuvants have been proposed.  
Year Model Antigenic Component Adjuvant(s) 
1989 Human (NANP)3-TT IFN alpha/gamma 
1990 Human Irradiated sporozoites None 
1990 Monkey p41/190N CFA/IFA 
1990 Monkey S7+S12+S17+SPf66 CFA/IFA 
1992 Human SPf66 Alum 
1992 Monkey E coli derived fusion proteins (MSAI, 
SERP, HRPII) 
Alum 
1992 Monkey E coli derived fusion proteins (MSAI, 
SERP, HRPII) 
Oil-based emulsion 
1992 Monkey Recombinant DNA-encoded fragment 
(C7Ag) of Pf p75 
Syntex adjuvant formulation/alum 
1993 Monkey SERA 1 CFA/IFA, MF59.2, MF75.2 
1995 Monkey SPf66 Alum 
1995 Monkey MSP1(42) and MSP1(19) Freund's 
1995 Human SPf66 Alum 
1996 Monkey NYVAC-Pf7, attenuated vaccinia virus 
expressing CSP, SSP2, LSA1, MSP1, 
SERA, AMA1, Pfs25 
None 
1996 Human SPf66 Alum 
1997 Human RTS,S Alum+MPLA/oil in water 
emulsion/emulsion+MPLA+QS21 
Table 3. Summary of malaria vaccines in development by year. This list of malaria 
vaccine candidates is the result of an extensive PubMed literature search using the key 
terms “malaria”, “vaccine”, and “adjuvant” from 1989 to 2018. The animal model, 




Year Model Antigenic Component Adjuvant(s) 
1997 Monkey Liver stage antigen 3 Freund's 
1997 Mouse MSA-2 Montanide ISA 720/SAF-1/liposomes 
with lipid A 
1998 Mouse AMA1 Montanide ISA 720/Freund's 
1999 Human MSP1 fragment+MSP2+RESA fragment Montanide ISA 720 
1999 Monkey Pf (T1B)4 multiple antigen peptides Freund's/alum/QS21 
2002 Mouse Recombinant BCG expressing CSP None 
2002 Mouse MSP1(19)+MSP4/5 Freund's 
2003 Human RTS,S AS02 
2003 Mouse SPf66 alum/PLGA microparticles 
2003 Monkey MSP1(42) and MSP1(19) Freund's 
2003 Human MSP1+MSP2+RESA Montanide ISA 720 
2004 Mouse MSP1(19)+MSP4/5 CpG ODN1826/Montanide ISA 51 
2004 Human PfCSP DNA prime + RTS,S/AS02A boost AS02A 
2004 Mouse Pan HLA DR-binding epitope carrier for 
MSP1(19) 
 
2004 Monkey RTS,S+TRAP AS02A 
2004 Mouse Recombinant Pv Duffy binding protein Montanide ISA 720/AS02A/Alum 
2004 Monkey MSP1(42) and MSP1(19) AS01B/AS02A/AS05/AS08 
2004 Mouse PcAMA and/or MSP1(42) Quil A 
2004 Human Modified hepatitis B virus core protein ICC-
1132 (Malarivax) 
Alum 
2005 Mouse EB200 DNA construct PfHSP70C 
2005 Monkey PfGRP and PfMSP3 Freund's/Montanide ISA 720 
2005 Human PfAMA1 Montanide ISA 720 
2005 Human ICC-1132 Montanide ISA 720 
2005 Human RTS,S AS02A 
2005 Monkey ICC-1132 Alhydrogel/Montanide ISA 720 
2006 Human FMP1 AS02A 
2006 Mouse PfMSP1(42) Montanide ISA 720/alum/MF59 
2007 Human FMP1 AS02A 
2006 Mouse AMA1-C1 Alhydrogel+CpG 7909 
2007 Human PfGLURP Alum/Montanide ISA 720 
2007 Mouse Recombinant F2(PfEBA-175) Montanide ISA 720/AS02A/Alum 
2007 Mouse Recombinant LSA1 AS01B/AS02A 




Year Model Antigenic Component Adjuvant(s) 
2006 Monkey Recombinant Pfs25H conjugated to 
OMP complex (N. meningitidis 
serogroup B) 
Alum 
2007 Monkey Replication-defective human Ad35.CS 
prime + RTS,S/AS01B boost 
AS01B 
2007 Human FMP2.1 AS02A 
2008 Human PfLSA1 alone or concurrently with 
RTS,S 
AS01B 
2008 Human AMA1/MSP1 chimeric protein Montanide ISA 720 
2008 Mouse AMA1+Pfs25 conjugated to P. 
aeruginosa ExoProtein A 
Alhydrogel +/- CpG 7909 
2008 Human Pfs25+Pvs25 Montanide ISA 51 - water in oil emulsion 
2008 Human AMA1-C1 Alhydrogel+CpG 7909 
2008 Mouse FALVAC-1A Alum/QS21/Montanide ISA 720/copolymer 
CRL-1005 
2008 Mouse MSP1(19) S. enterica serovar Typhimurium flagellin-
TLR5 agonist (mixed or linked) 
2009 Mouse PfCS peptides subQ topical imiquimod 
2008 Human RTS,S AS01E 
2008 Human PfAMA1 Alhydrogel/Montanide ISA 720/AS02 
2008 Mouse PbCSP modified E. coli heat-labile toxin 
2009 Mouse PfMSP4/5 CFA versus AFCo1 
2009 Human RTS,S AS02 
2009 Human AMA1 AS01B/AS02A 
2009 Human AMA1-C1 Alhydrogel+CpG 7909 
2009 Monkey PvRAP2 Freund's/Alum 
2009 Human AMA1-C1 Alhydrogel 
2010 Human LSA-NRC AS01/AS02 
2009 Monkey PvMSP10 Freund's/Montanide ISA 720/Alum 
2009 Human RTS,S AS02D/AS01E 
2009 Human AMA1-C1 Alhydrogel+CpG 7909 
2010 Mouse PfMSP-Fu(24) chimeric protein from 
MSP1(19) and MSP3(11) 
CFA/IFA/Montanide ISA 720/Alum 
2010 Mouse Recombinant Pvs25 non-toxic cholera toxin B subunit delivery 
system 
2010 Mouse Pf332-DBL Montanide ISA 720/alum/levamisole 
2010 Human EBA-175 Alum 
2010 Monkey PfCSP or antiDEC-CSP Poly (I:C) 
2011 Mouse GLURP-MSP3 GLA 
Table 3 (continued). Summary of malaria vaccines in development by year.  
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Year Model Antigenic Component Adjuvant(s) 
2011 Monkey PkAMA1 CoVaccine HT 
2011 Monkey VMP001 chimeric recombinant 
PvCSP 
GLA-SE 
2011 Human EcMSP2-3D7 and EcMSP2-FC27 Montanide ISA 720 
2012 Human VAR2CSA DBL4e-ID4 Montanide ISA 720/Alhydrogel/CAF01 
2011 Mouse Virosomes with MSP3 and 
GLURP 
Alum/Montanide ISA 720 
2012 Mouse Recombinant BCG expressing 
SE22 from the N terminal domain 
of SERA 
None 
2012 Human BSAM2 (FVO and 3D7 alleles of 
rAMA1 and rMSP1(42) 
Alhydrogel+CpG 7909 
2013 Monkey SE36/AHG K3 ODN/D3 ODN/synthetic hemozoin 
2013 Human PfFVO MSP1(42) AS01 
2013 Mouse LbL polypeptide films on solid 
CaCO3 cores containing a tri-
epitope CS peptide 
Pam3Cys 
2013 Mouse Pfs25H-EPA conjugated 
nanoparticle 
Alhydrogel 
2014 Human RTS,S+TRAP AS02 
2014 Mouse Recombinant CSP from 
Pseudomonas fluorescens 
 
2015 Human JAIVAC-1 (rPfMSP1(19) + 
rEBA175) 
Montanide ISA 720 
2015 Mouse Library of CS epitopes on 
woodchuck hepatitis virus core 
antigen VLP 
IFA/Alum 
2016 Human FMP2.1 (3D7 AMA1) AS01 
2016 Mouse E coli OMV expressing AnAPN1 
and Pfs48/45 
Intranasal: Cholera Toxin/Parenteral: MF59C.1 
2017 Mouse PfUIS3 in viral vectors 
ChAd63/MVA with PfTRAP 
 
2017 Mouse FMP014 (60 identical monomber 
protein chains that self-assemble 
into nanoparticles) 
Army Liposomal Formulation (ALF; liposomal 
adjuvant containing MPLA) 
2017 Mouse PvTRAP-VLP Microcrystalline tyrosine 
2017 Mouse FMP013 (nearly full length CSP 
from 3D7) 
ALF alone/ALF+Alum/ALF+QS21/Montanide ISA 
720 
2017 Mouse Full length rPfCSP CAF09 
2017 Human PfAMA1-DiCo GLA-SE/Alhydrogel 
2017 Mouse Self-assembling protein 
nanoparticles with PfCSP 
TLR5 agonist flagellin 
2018 Mouse PfMSP1(42) Poly (I:C)/CFA/IFA 
Table 3 (continued). Summary of malaria vaccines in development by year.  
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The most employed adjuvants in developing malaria vaccines are aluminum salts, 
Montanide ISA 720, and Adjuvant Systems AS01/AS02. One reason for biased adjuvant 
incorporation is that these adjuvants are also delivery systems for the vaccine antigen. 
Another reason may be their availability and well-defined tolerability. Aluminum salt 
formulations and Montanide ISA 720 are readily available for purchase, and although 
GSK’s Adjuvant Systems are proprietary, they collaborate with developers of multiple 
malaria vaccines candidates. Additionally, several malaria vaccine formulations 
incorporate a TLR ligand (50-54).  
 
The RTS,S vaccine, the most advanced malaria vaccine candidate to date, has 
undergone several revisions to the adjuvant formulation. Early formulations of RTS,S 
compared three adjuvants: Alum/MPLA (TLR4 agonist), oil-in-water emulsion, oil-in-
water emulsion plus MPLA/QS-21 (saponin derivative) (55). Circumsporozoite antibody 
titers were most elevated following three doses of RTS,S with the oil-in-water emulsion 
plus MPLA/QS-21. It is now appreciated that emulsion-based adjuvants induce Th2 
responses associated with elevated antibody titers. For the next decade of evaluation, 
the RTS,S vaccine adjuvant formulation contained similar components, an a-
tocopherol/squalene oil-in-water emulsion with MPL/QS-21 (also known as AS02). In 
2008, AS01, a more immunogenic adjuvant containing liposomes instead of an oil-in-
water emulsion, was introduced with RTS,S (56). The vaccine efficacy of RTS,S/AS01 
(53%) was promising in comparison to the previous RTS,S/AS02 formulation (30%). 
RTS,S/AS01 is the current vaccine formulation employed in large-scale pilot studies (2). 
The phase III trial demonstrated the RTS,S/AS01 vaccine efficacy to be less than 30%. 
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It is clear that this vaccine alone will need additional interventions to be effective. Future 
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PRR ligands are small molecules that target either cell membrane or cytosolic receptors 
of the innate immune response, triggering various signaling cascades and, ultimately, 
activating the adaptive immune response (1). The ability of these PRR ligands to 
stimulate a variety of cell types required for an effective immune response makes them 
good vaccine adjuvant candidates (2). The PRR ligands of interest to our lab as 
potential vaccine adjuvants and their receptors include: Polyinosine-polycytidylic acid 
(Poly (I:C), TLR3), Glucopyranosyl lipid A (GLA, TLR4), Imidazoquinoline (R848, 
TLR7/8), γ-D-Glu-mDAP (iE-DAP, Nod1), CpG ODN 2006 (CpG, TLR9), and trehalose-
6,6-dibehenate (TDB, C-type lectin Mincle). 
 
Germinal center formation is key to the production of high affinity antibodies and B cell 
memory (3), two critical elements of immunity to many viral, bacterial, and protozoan 
pathogens, including malaria.  Our lab is interested in the effects of PRR ligands on B 
cell subsets important to the formation of functional germinal centers. These B cell 
subsets include transitional, marginal zone (MZ), and follicular (Fo) B cells which 
contribute to the development, structure, and function of germinal centers.  While Notch 
signaling plays a role in certain B cell fate decisions (4), the broader effects of PRR 
ligands on gene expression during early stages of B cell maturation are not fully 
understood. In addition, MZ and Fo B cells have been implicated in the differentiation 
and maintenance of T follicular helper (Tfh) cells and the interaction between B cells 
and Tfh cells constitutes a limiting step in the selection of high affinity B cells.  
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Various infections, including malaria, disrupt B cell lymphopoiesis. During malaria 
infection, transitional and MZ B cells are among the populations disturbed (5-7), 
however, how their functional properties may be affected has not been fully elucidated.  
 
The overall goals of our project are to evaluate the capacity of PRR ligands to drive the 
maturation, differentiation, and activation of B cell subsets. We hypothesize that select 
PRR ligands will effectively drive the maturation and activation of B cell subsets. These 
PRR ligands will be idea adjuvant candidates for vaccines requiring a robust antibody 
response. Additionally, information gained about the effects of PRR ligands on human B 
cells will aid in future rational design of vaccine adjuvants.  
 
 
Specific Aim 1. Identify the direct effects of PRR ligands on human B cell 
development. 
PRR ligands can bind to receptors on human B cells at a variety of developmental 
stages, including immature transitional B cells, mature follicular B cells and marginal 
zone B cells.  In Specific Aim 1A, we will determine which PRR ligands are capable of 
driving the maturation of transitional B cells into Fo or MZ B cells and how these PRR 
ligand effects may be altered by BCR ligation. In Specific Aim 1B we will study the 
ability of PRR ligands with and without BCR ligation to activate mature B cells. PRR 
ligands that drive follicular B cell maturation and activation will be ideal adjuvant 
candidates for vaccines requiring long-lived memory and antibody responses, as the 
follicular B cell subset represents the precursors of germinal center B cells. 
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Hypothesis 
We hypothesize that select PRR ligands will drive transitional B cells to mature into Fo 
B cells, while others will drive MZ B cell maturation.  
Approach 
Specific Aim 1A. Identify PRR ligands that drive the differentiation of transitional 
B cells into marginal zone-like (MZ-like) or follicular (Fo) B cells 
The goal of this aim is to use flow cytometry to isolate three B cell subsets (transitional, 
marginal zone-like and follicular) from human primary mononuclear cells and analyze 
the ability of PRR ligands to drive their differentiation. Transitional B cell subsets (T1, 
T2, T3) will be characterized by surface antigen expression in human cord blood 
mononuclear cells (Hemacare, Van Nuys, CA) and human peripheral blood 
mononuclear cells from adult volunteers.  Transitional B cells will be isolated from 
human cord blood mononuclear cells by flow cytometry as CD19+ CD24+/hi CD38+/hi 
Rhodamine 123+ cells (8). Sorted transitional B cells will be cultured in the presence of 
IL-4, a known survival factor for human transitional B cells, with or without PRR ligands 
and anti-IgM. Following culture for 2-4 days, cells will be analyzed by flow cytometry to 
determine the percentage of cells with a MZ-like (CD19+ CD21+/- CD23-) or Fo (CD19+ 
CD21+/- CD23+) B cell phenotype. Rhodamine 123 retention will be used to identify B 
cells that remain immature.  
 
Specific Aim 1B. Identify PRR ligands that activate tonsillar MZ-like or Fo B cells. 
The goal of this aim is to use flow cytometry to isolate marginal zone-like and follicular B 
cells from human primary mononuclear cells and analyze the ability of PRR ligands and 
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BCR ligation to drive their activation. Human tonsils (Kapiolani Medical Center, 
Honolulu, HI) will be obtained and subsequently dissociated for FACS sorting. Cells will 
be stained for MZ-like and Fo B cell surface markers as described above and sorted 
into two separate populations. Sorted MZ-like and Fo B cells will be cultured overnight 
with individual PRR ligands with and without anti-IgM. Following overnight culture, cells 
will be recovered and costimulatory/activation molecules (CD86 and MHCII) and 
immunoglobulin expression will be analyzed.  
 
 
Specific Aim 2. Evaluate the transcriptomic profiles of human B cell subsets 
Several signaling pathways and transcription factors have been associated with B cell 
maturation from immature transitional B cells to mature naïve follicular and marginal 
zone B cells. However, to date, the transcriptomic profiles of human transitional, 
follicular and marginal zone B cells have not been evaluated concurrently. Specific Aim 
2A will analyze the transcriptome of these B cell subsets. Notch signaling and E 
proteins have been reported to play a key role in the cell fate determination of murine 
mature B cells, in Specific Aim 2B we will determine whether these genes also play a 
key role in human mature B cells. In Specific Aim 2C, we will evaluate the ability of PRR 
ligands to initiate Notch signaling as well as signaling through other pathways that 
potentially affect B cell maturation of immature transitional B cells into mature follicular 





We hypothesize that genes involved in Notch signaling, murine B cell maturation, and 
select pathways identified following transcriptome analysis will characterize mature 
human Fo and MZ B cells. These genes will be differentially expressed following the 
stimulation of immature transitional B cells with select PRR ligands. 
Approach 
Specific Aim 2A. Transcriptome analysis of transitional, follicular, and marginal 
zone B cells 
The goal of this aim is to use flow cytometry and AmpliSeq technology to analyze the 
transcriptome of human cord blood transitional B cells, human tonsillar follicular B cells 
and human tonsillar marginal zone B cells. Each B cell subset will be isolated by flow 
cytometry and RNA will be extracted for downstream library preparation and RNA 
sequencing. Bioinformatics analysis of differential gene expression will be assessed to 
identify genes associated with human B cell lineage commitment. Raw reads will be 
quality controlled and aligned to the human genome using STAR. Differential 
expression will be analyzed using the DESeq2 software package, visualized using R 
and pathway and network analysis will be performed using Ingenuity Pathway Analysis 
(IPA). 
 
Specific Aim 2B. Gene expression analysis of tonsillar follicular and marginal 
zone B cells 
The goal of this aim is to use real-time qPCR to compare the expression of Notch 
signaling components and maturation genes of human tonsillar follicular and marginal 
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zone B cells to their murine splenic counterparts. Following FACS isolation of follicular 
and marginal zone B cells according to their previously stated cell surface markers, 
RNA will be isolated, and cDNA will be synthesized. Real-time qPCR will be performed 
using primers for 15 genes encoding B cell specific Notch signaling components and 7 
genes involved in B cell maturation. 
 
B cell-specific Notch signaling genes B cell maturation genes 
ADAM10 HES5 JAG1 NCSTN NUMB BTK ASB2 
GLI1 HEY2 LFNG NOTCH2 RBPJL ID2 TCF3 
HES1 HEYL NCOR NOTCH2NL SNW1 ID3  
Table 1. List of genes evaluated in B cell populations by real-time qPCR. 
 
Specific Aim 2C. Gene expression analysis during transitional B cell 
differentiation. 
The goal of this aim is to use flow cytometry and real-time qPCR to evaluate the role of 
Notch signaling and other lineage commitment genes identified by AmpliSeq analysis 
during normal B cell development and determine whether PRR ligands can skew B cell 
development by directly affecting a subset of these genes. Human transitional B cells 
will be FACS-sorted according to their previously stated cell surface markers. Following 
culture with PRR ligands, RNA will be isolated, and cDNA will be synthesized. Control 
cultures will include no PRR stimulation. To analyze the relative expression of Notch 
signaling transcripts, cDNA will be added to PrimePCR Array plates containing primers 
specific for more than 40 gene targets important to the Notch signaling pathway. Real-
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time qPCR will also be used to evaluate expression of other B cell maturation-
associated genes identified in the RNA Seq studies. 
 
Human Subjects Research 
For Aim 1 & 2A-C, human peripheral blood, cord blood and tonsils will be used. Human 
peripheral blood is obtained following informed consent. No identifying information will 
be collected. Human cord blood is purchased from a commercial vendor. Human tonsils 
are provided as exempt tissues from routine tonsillectomies by our clinical collaborator, 
Dr. Patrick O’Donnell at Kapiolani Medical Center. No identifying information is 
provided. This study has been reviewed and approved by the University of Hawaii 
Human Studies Program.  
 
Relevance 
Small molecular adjuvants are in clinical and experimental use (9), however, their 
effects on specific human B cell subsets are not fully understood. Since a vaccine’s goal 
is to establish a robust antibody response, it is important to understand the ability of the 
vaccine adjuvant to drive B cell development and activation. Adjuvants may skew the 
resulting immune response by acting directly on B cell functions or indirectly by affecting 
antigen presenting cells and T helper cell development. This proposal will investigate 
the direct effects of select molecular adjuvants on human B cell subsets. Understanding 





While vaccines are considered to be one of the most effective methods to control 
communicable diseases, there are no approved vaccines for many infectious diseases 
including malaria, HIV/AIDS, dengue and West Nile virus (10). Candidate vaccines for 
malaria and dengue have provided promising results in Phase III clinical trials. The most 
advanced malaria vaccine candidate with moderate effectiveness, RTS,S/AS01, is 
being assessed in several large-scale pilot implementations in sub-Saharan Africa (11). 
A recently published study (12) analyzed the immunogenicity of this vaccine over time 
to assess the waning of immunity. Differences in vaccine efficacy were age- and 
exposure-dependent, with anti-circumsporozoite antibodies waning rapidly in the first 6 
months followed by a slower decline over the next 4 years. Therefore, improved efficacy 
and long-term memory induction is still needed to make this vaccine a successful public 
health tool. One of the potential approaches to improve subunit vaccine efficacy and 
durability is through the use of adjuvants. While RTS,S/AS01 consists of a liposome-
based adjuvant system containing monophosphoryl lipid A (MPL) and the saponin QS-
21, other adjuvant systems may yield more efficacious and longer-lasting responses. 
There are a variety of possible adjuvants in development, however, much of the 
rationale for choosing an adjuvant is empirical, rather than mechanistic (13). To date, 
there are only a handful of adjuvant formulations licensed for use in human vaccines, of 
which four are licensed for use in the US, including alum (14). The lack of safe and 




PRR ligands and B cells 
Vaccine adjuvant candidates to date include PRR ligands, oil-in-water emulsions, 
saponins, liposomes, and nanoparticles, alone or in combination (15). PRR ligands are 
small, immunostimulatory molecules that target either cell membrane or cytosolic 
receptors of the innate immune response, trigger various signaling cascades leading to 
an activated adaptive immune response (2). Various studies have shown that mouse 
and human B cells increase co-stimulatory molecule expression, secrete IgM 
antibodies, and proliferate in response to different PRR ligands (16-20). Of interest to 
our lab are the effects of these PRR ligands on B cell subsets important to functional 
germinal centers. Germinal center formation is key to the production of high affinity 
antibodies and B cell memory (21), two critical elements of immunity to many viral, 
bacterial, and protozoan pathogens, including malaria. Transitional, marginal zone (MZ), 
and follicular (Fo) B cells contribute to the development, structure, and function of 
germinal centers and extrafollicular immune responses (22). In addition, MZ and Fo B 
cells have been implicated in the differentiation and maintenance of T follicular helper 
(Tfh) cells (23), the limiting factor in the maturation of high affinity B cells. Current 
information on PRR expression of human B cell subsets is limited as most analysis is 
done with the B cell population as a whole (24-26).  
 
B cell subsets of the human tonsil 
Human palatine tonsils are secondary lymphoid organs of the nasopharynx-associated 
lymphoid tissue (27, 28). Secondary lymphoid organs contain B cell follicles that 
develop into germinal centers, sites of intense B cell proliferation, affinity maturation, 
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and isotype class switching in response to vaccination or infection (21). The B cell 
populations present in the human tonsil include: follicular B cells, marginal zone-like B 
cells, germinal center B cells, newly formed memory B cells and plasmablasts (29). 
While localized to the tonsil at the time of vaccination or infection, the resulting memory 




Need to define adjuvant effects on human B cell subsets 
The vast majority of research examining the effects of PRR ligands on B cell subsets 
has been done using the mouse model. While some work has been done examining the 
effects of PRR ligands on B cells in humans, most of that work examines the effects of 
PRR ligands on the B cell population as a whole (25, 30). Yet, the B cell population is 
very heterogeneous. Functionally distinct subsets can reside in the same tissue while 
similar B cell subsets will have different functionalities in different tissues. This project 
will tease out the different effects PRR ligands have on human B cell subsets present in 
cord blood and the tonsils.  
 
Human cord blood and tonsils as B cell sources 
Human cord blood contains approximately 5-10% CD19+ B cells with the majority of 
those having a transitional B cell phenotype. This is the most enriched source of human 
transitional B cells available. In comparison, approximately 5-20% of lymphocytes in 
adult peripheral blood are B cells, of which only about 4% are transitional B cells. 
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Tonsils are the most accessible human secondary lymphoid organs. B cells represent 
approximately 80% of tonsil lymphocytes. Five B cell subsets based on IgD and CD38 
expression are present in human tonsils: naïve B cells (~30%), pre-germinal center B 
cells (~10-15%), germinal center B cells and plasmablasts (~40%), and memory B cells 
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While vaccination is recognized as one of the most effective approaches for infectious 
disease prevention, there is a pressing need for safe and effective immune modulators 
also known as “adjuvants”, to enhance the effectiveness and durability of many current 
and experimental vaccines, particularly for the very young and the elderly (1, 2). The 
identification of pattern-recognition receptor (PRR) ligands or pathogen-associated 
molecular patterns (PAMPS) as potent immune modulators has led to their evaluation 
as vaccine adjuvants. Some vaccines contain naturally occurring PAMPS like viral 
nucleic acids in the Yellow Fever vaccine, while others utilize additional PRR ligands 
like MPL, a TLR4 ligand adsorbed to alum, in the recombinant HPV vaccine Cervarix (3, 
4). Much of the previous research investigating the cellular effects of PRR ligands has 
focused on their effects on antigen-presenting cells (5-7), however B cells also are 
potential responders to PRR stimulation and are of interest as direct targets of adjuvant 
immunomodulation.  
 
Mechanistic studies of PRR ligand adjuvant activity in the mouse model have provided 
important insights into the influence of PAMPS on the immune response, however 
mechanisms defined in the mouse model often do not translate directly to humans (8, 
9). In addition, the spectrum of potential PRR receptors has increased in recent years 
and now includes Toll-like receptors (TLRs), Nod-like receptors (NLRs), and C-type 
lectin receptors (CLRs), among others (10). While the effects of a few PRR ligands on 
human B cells have been explored (11, 12), knowledge of their contribution to the 
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differentiation and activation of B cell subsets important to germinal center formation, a 
critical feature of effective antibody-mediated immunity, is limited.  
 
Transitional B cells are important intermediates in the development of mature B cells 
(13). Transitional B cells are immature B cells that have recently migrated from the bone 
marrow to the periphery following expression of a functional B cell receptor (14). After 
selection and further differentiation, they give rise in secondary lymphoid organs to 
mature B cell populations, including follicular (Fo) B cells and marginal zone (MZ) B 
cells. Fo B cells play a central role in germinal center formation in response to T cell-
dependent antigens, and are responsible for the production of high-affinity, class-
switched antibody, and differentiate into long-lived plasma cells and memory B cells 
(15). MZ B cells respond to blood borne pathogens and T-independent type 2 antigens, 
differentiate into short-lived plasma cells, and also play a role in antigen capture and 
shuttling to follicular dendritic cells (16, 17).  
 
Total B cell and B cell subset frequencies vary depending on an individual’s age. In 
addition to the gradual decrease in total B cell count from newborn to six years of age, 
there is a switch in prominent B cell populations from mostly immature/transitional B 
cells in early childhood to mature and memory B cells in young adults (18). Since many 
current vaccines and vaccines in development are administered during childhood, it is 
important to examine the effects of vaccine components like PRR ligands on the 
prominent transitional B cell population in newborns and young children. In addition to 
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antigen-specific B cell receptors, transitional B cells express several PRRs in addition to 
antigen-specific B cell receptors that may play a role in their maturation (19). 
Transitional B cells may encounter PRR ligands during infection or immunization; 
however, the response of human transitional B cells to these stimuli remains largely 
unknown. To date, the effects of only select TLR ligands on transitional B cells have 
been explored (20-23). To fully understand the adjuvant potential of a range of PRR 
ligands, it is important to explore their potential effects on the development of immature, 
peripheral B cells as their maturation and differentiation will produce B cell populations 
that participate in the germinal center reaction and in germinal-center independent 
immune responses. The current study explores the effects of PRR ligands, currently 
being investigated as vaccine adjuvants, on the maturation of human transitional B cells 
into follicular B cells, as demonstrated by surface phenotype and gene expression 
changes.  
 
2. Materials and Methods 
2.1. B cell isolation 
Cryopreserved human cord blood mononuclear cells were obtained from Hemacare 
(Van Nuys, CA), Lonza (Alpharetta, GA), and STEMCELL Technologies Inc. 
(Vancouver, BC) and used as a source of transitional B cells. Human tonsils were 
obtained following routine tonsillectomies from the Kapi’olani Medical Center for Women 
and Children, Hawai‘i Pacific Health System (Honolulu, HI) and were used as a source 
of mature, Fo B cells. These studies were reviewed and determined not to be human 
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subjects research by the institutional review boards of the University of Hawai‘i and 
Hawai‘i Pacific Health. Freshly isolated tonsils were soaked overnight in Hank’s 
Buffered Saline Solution (HBSS; Thermo Fisher Scientific, Waltham, MA, USA) with 1x 
penicillin-streptomycin. Tonsils were minced and homogenized through a 40um cell 
strainer. Tonsil mononuclear cells were isolated by density-gradient centrifugation using 
Ficoll-Hypaque (GE Healthcare, Chicago, Il, USA). Mononuclear cells were collected at 
the interphase and washed in 1x HBSS. All cells were resuspended in HBSS with 2% 
fetal bovine serum for downstream fluorescence-activated cell sorting (FACS) and 
analysis. 
 
2.2. Antibodies and reagents 
The following fluorochrome-conjugated anti-human antibodies and fluorescent dyes 
were used for flow cytometry analyses: CD19-BV605, CD3-BV421, and CD23-BV421 
(BD Biosciences, Franklin Lakes, NJ, USA); IgM-APC (Biolegend, San Diego, CA, 
USA); and CD19-eVolve 605, CD38-PE-eFluor 610, CD24-APC-eFluor 780, CD21-
PerCP-eFluor710, FcRL4-PerCP-eFluor 710, IgD-PE, CD5-APC, 7AAD, Fixable 
Viability Dye eFluor 506, Propidium Iodide, Rhodamine 123 (Thermo Fisher Scientific). 
Resiquimod (R848) and glucopyranosyl lipid A (GLA) were obtained from the Infectious 
Disease Research Institute (Seattle, WA). C12-iE-DAP (iE-DAP), polyinosinic-
polycytidylic (Poly I:C), trehalose-6,6-dibehenate (TDB), and CpG ODN 2006 (CpG) 
were purchased from InvivoGen (San Diego, CA). 
2.3. Transitional B cell culture conditions 
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FACS-sorted transitional B cells (CD3- CD19+ Rhodamine123hi CD24+ CD38+) were 
seeded in a 96-well U-bottom plate at 5 x 105 cells/mL in RPMI containing 10% FBS 
and 1x penicillin-streptomycin (Thermo Fisher Scientific). Transitional B cells were 
cultured in medium supplemented with IL-4 (100ng/mL; PeproTech, Rocky Hill, NJ, 
USA), R848 (TLR7/8 ligand; 5ng/uL), GLA (TLR4 ligand; 2ng/uL), CpG ODN 2006 
(TLR9 ligand; 0.25uM), iE-DAP (NOD1 ligand; 2.22ng/uL), TDB (Mincle ligand; 
20ng/uL), Poly(I:C) (TLR3 ligand; 20ng/uL), or anti-IgM/IgG (Jackson ImmunoResearch; 
20ug/mL, 10ug/mL, and 2ug/mL). After 2 and 4 days, transitional B cell cultures were 
analyzed for mature Fo B cell surface markers (CD19+ R123lo CD23+) by flow 
cytometry. Each experiment was repeated at least 4 times. Representative data and 
compiled results of replicate experiments are shown.  
 
2.4. Flow cytometric analysis 
Flow cytometry sorting and analyses were performed on a FACSAria instrument (BD 
Biosciences, San Jose, CA) and an Attune NxT instrument, respectively (Thermo Fisher 
Scientific) at the Cellular and Molecular Immunology Core Facility at the John A. Burns 
School of Medicine, University of Hawai‘i at Mānoa. Cells were stained with the 
appropriate antibodies and incubated in the dark at 4°C for 30 minutes. Cells were then 
washed twice and resuspended in 1x HBSS supplemented with 2% FBS for sorting and 
analyses. Analyses were performed using FlowJo data analysis software (FlowJo, 
Ashland, OR). 
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2.5. RNA Sequencing 
Cord blood transitional B cells and tonsil follicular B cells were sorted and total RNA 
was extracted using the RNeasy Mini kit (Qiagen, Germantown, MD). Total RNA was 
submitted to the Genomics Shared Resource at the University of Hawaii – Cancer 
Center for library preparation and sequencing. Total RNA was quantified, and quality 
checked using the Bioanalyzer RNA 2100 Pico instrument (Agilent, Santa Clara, CA). 
Libraries were prepared with AmpliSeq for Illumina Transcriptome Human Gene 
Expression Panel (Illumina, San Diego, CA). Sequencing was performed on a NextSeq 
500 (Illumina, San Diego, CA). Raw FASTQ files were transferred to the Bioinformatics 
core at the John A. Burns School of Medicine, University of Hawai‘i at Manoa for 
analysis. Raw reads were processed using CutAdapt (24) and aligned to human 
genome (hg38) using STAR (25). Gene counts were quantified using Partek E/M 
Quantification (Partek Inc., St. Louis, MO). DESeq2 (26) was used to analyze 
differential gene expression and data were visualized using R. Ingenuity Pathway 
Analysis (Qiagen Bioinformatics, Redwood City, CA) was used for pathway and network 
analysis. 
 
2.6. Real-time qPCR 
Total RNA was reverse-transcribed into cDNA using the cDNA synthesis kit (Bio-Rad 
Laboratories, Hercules, CA, USA). For AmpliSeq confirmation and gene expression 
analysis following transitional B cell stimulation, cDNA was added to SYBR Green 
Supermix (Bio-Rad Laboratories) and FCER2, PTPN6, ADAM28, RUNX1, RUNX2, 
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PRDM1, and CD27 primers (Qiagen). All real-time qPCR analyses were run on an 
Applied Biosystems 7500 Real-Time PCR System (Thermo Fisher Scientific). 
Expression fold-change was calculated using ACTB as the housekeeping gene. 
 
2.7. Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, San 
Diego, Ca). Unpaired Student’s t tests were employed where appropriate. Data are 
represented as means +/- SEM. Statistical significance was determined as follows: p > 
0.05 (not significant), *p ≤ 0.05, or **p ≤ 0.01 (significant). 
 
3. Results 
3.1. Identification of transitional B cell subset from human cord blood and peripheral 
blood 
Transitional B cells are the recent emigrant B cells from the bone marrow. Following 
successful migration in the periphery to secondary lymphoid organs, transitional B cells 
differentiate into mature naïve MZ or Fo B cells. In order to study human transitional B 
cells, we isolated these cells from cord blood, the richest source of human transitional B 
cells. Three subsets of transitional B cells, found in the CD19+ CD24+ CD38+ population 
(14, 27), were identified from cord blood by flow cytometry. Since some mature B cells 
were also found in the CD24+ CD38+ population, rhodamine 123 (R123) retention was 
used as an additional marker for transitional B cells, which do not express the ABCB1 
transporter responsible for efflux of R123 (28). In contrast, mature B cells express 
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ABCB1 and extrude this dye (29). Approximately 50% of cord blood B cells have a 
transitional phenotype as defined by bright staining for R123 (Figure 1A) and high levels 
of CD24 and CD38 expression (Figure 1B). Consistent with the reports of others (30, 
31), cord blood R123hi transitional B cells also were characterized by high IgM and IgD 
expression and low to no expression of CD23 (Fig. 1B). While cord blood R123lo cells 
also expressed sIgM and sIgD, their expression of these markers was more 
heterogenous than the R123hi population. Moderate CD21 expression was observed in 
both R123hi and R123lo B cells.  
 
CD24hi CD38hi transitional B cells are also found in human peripheral blood, however, at 
a much lower frequency (approximately 4% of total CD19+ cells) (Figure 1D). Peripheral 
transitional B cells were more heterogeneous in their expression of the various cell 
surface markers than R123hi cord blood transitional B cells, similar to R123lo cord blood 
B cells (Figure 1B). Naïve (IgD+ CD27-) cord blood B cells and adult peripheral blood B 
cells are known to express TLR 1, 2, 4-10, with the highest levels of TLR 7, 9, 10 (12). 
Expression of these TLRs suggest that cord blood B cells, including transitional B cells, 
have the potential to respond to TLR agonists. Because we were interested in the ability 
of PRR ligands to induce maturation of transitional B cells into follicular B cells, we 
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3.2. Transitional B cells mature following PRR stimulation 
We were interested in determining whether select PRR ligands have the ability to drive 
the maturation of transitional B cells. Mature B cell subsets found in human secondary 
lymphoid organs, such as tonsils, express varying levels of surface CD21, CD23, IgD, 
and IgM (32, 33). CD23 expression has been used as a marker of mature, follicular B 
cells (34-37). Therefore, we utilized relative CD23 expression to evaluate B cell 
maturation in transitional B cell cultures.  
 
Preliminary studies of transitional B cells cultured in standard culture medium resulted in 
a very low level of B cell survival, consistent with the apoptotic fate of most transitional 
B cells (27).  B cell recovery was greatly improved when the anti-apoptotic cytokine IL-4 
was added (data not shown).  Therefore, IL-4 was included in all transitional B cell 
cultures unless otherwise noted.   
 
To evaluate transitional B cell maturation, we stimulated highly purified cultures of CD3- 
CD19+ R123hi CD24+ CD38+ transitional B cells (>95% purity) for 48- and 96-hours with 
PRR ligands and IL-4. Cell surface marker expression levels were the same for both 48- 
and 96-hour cultures, therefore only 48-hour results are reported. A subpopulation of 
human B cells expressing variable levels of CD23 was recovered after culture of 
transitional B cells in the presence of IL-4 alone (Figure 3A), including some cells 
expressing intermediate levels of CD23, probably corresponding to maturing T2 cells, 
and others expressing high levels of CD23, corresponding to mature, naïve B cells (29).  
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IL-4 has been found to induce CD23 expression and the maturation of bone marrow 
derived transitional B cells in mice (38). 
 
The addition of R848, iE-DAP, and CpG to IL-4 containing cultures enhanced the 
maturation of transitional B cells to CD23hi mature B cells, with very few CD23- cells 
remaining at 48 h (Figure 3B, D, G). Interestingly, CpG alone (without added IL-4) 
preserved transitional B cell viability (data not shown) and induced intermediate levels 
of CD23 expression, however relatively few cells expressed high levels of CD23 (Figure 
3H). In cultures containing TDB plus IL-4, transitional B cells retained a mostly CD23 
negative phenotype, with a lower percentage of CD23 high or intermediate cells as 
compared to IL-4 cultures (Figure 3F). CD23hi cells were present at a lower level in 
these cultures than in IL-4 only cultures. Cultures stimulated with TDB + IL-4 also 
contained a higher percentage of CD23- CD21+ cells than cultures receiving IL-4 alone 
or IL-4 and other PRR ligands (Figure 6F). Poly I:C and GLA had little effect on the 
differentiation of transitional B cells relative to IL-4 alone (Figure 3C, E).  
 
This overall pattern of responsiveness was consistent for cord blood transitional B cell 
samples from five individuals (Figure 3I-K). Transitional B cells stimulated with R848 
plus IL-4 and CpG plus IL-4 yielded the highest percentage of CD23hi cells (Figure 3I: 
R848+IL4 vs. IL4, p=0.0148; CpG+IL4 vs. IL4, p=0.0017) although CD23 MFIs were not 
significantly different from IL-4 cultures (Figure 3J). Transitional B cells stimulated with 
CpG alone resulted in little to no increase in CD23hi cells as compared to IL-4 cultures 
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and these CD23+ cells displayed a statistically significant lower CD23 MFI than CpG 
plus IL-4 (P=0.0259; Figure 3I, J). Transitional B cells express CD21 with little to no 
CD23 prior to stimulation with PRR ligands (Figure 1). Interestingly, the frequency of 
CD23- CD21+ cells was higher in cultures stimulated with TDB plus IL-4 (p=0.0476) and 
CpG alone (not significant) as compared to IL-4 cultures, while other stimulation 
conditions resulted in an average of less than 3% of CD19+ B cells displaying the CD23- 
CD21+ phenotype (Figure 3K). These CD23- CD21+ cells may correspond to either 
transitional B cells that have yet to complete B cell maturation or that are differentiating 
along the marginal zone B cell pathway. 
 
3.3. Transitional B cell stimulation may drive marginal zone precursor population 
The previous analysis focused on the expression of CD23 as a marker of B cell 
maturation, although it serves primarily as an indication of Fo B cell differentiation.  The 
ATP-binding cassette (ABC) B1 transporter has been identified as a marker that 
discriminates naïve B cells from transitional and all memory B cells (28). The acquisition 
of ABCB1, as reflected in its ability to extrude the fluorescent dye Rhodamine 123 
(R123) from cells, may be used to follow the development of transitional B cells into 
mature naïve B cells including those that do not fall within the CD23+ population.   
 
Transitional B cells (CD19+ CD24+ CD38+) from cord blood mononuclear cells 
containing T1, T2, and T3 stages (mainly T1/T2 populations) have been differentiated 
from mature B cells by their R123, CD24, and CD38 staining intensity (29). Prior to 
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culture, R123hi transitional B cells were CD23- CD21lo/- with variable IgM and high IgD 
expression (Figure 4A, red population,). R123lo cord blood B cells correspond to 
maturing B cells that have begun to efflux R123 via the ABCB1 transporter. These cells 
were mostly CD23- CD21lo/- IgD+ with varying levels of IgM expression, however the 
R123lo population also contained some IgM- and IgD- cells (blue populations, Figure 
4A).  
 
Culture of purified transitional B cells for two days with IL-4, resulted in the emergence 
of maturing B cell populations that expel varying amounts of the R123 (Figure 4B, blue) 
as well as a small peak of R123-negative, fully-mature B cells. Maturing B cells have 
begun to express varying amounts of CD23 with low amounts of CD21.  The residual 
R123hi cells in these cultures were also positive for CD23. After IL-4 culture, R123hi, 
R123lo, and R123- populations have increased surface IgM/IgD expression, although a 
minor subpopulation of R123- mature B cells were negative for both IgM and IgD.  
 
Cells cultured with IL-4 plus R848 generally displayed a higher proportion of fully mature 
B cells than IL-4 cultures (Figure 4C). These R123- B cells included distinct 
subpopulations of CD23-, CD23int, and CD23hi cells, with a majority of cells being 
CD23hi. Similar to IL-4 cultures, the remaining R123hi population was distinct from the 
original transitional B cells population with respect to CD23, IgM and IgD expression.  
Interestingly, these remaining R123hi cells were all CD23hi, suggesting that CD23 
expression increased prior to ABCB1 induction. The R123lo population contains a 
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majority of IgM+/IgD+ and a minority of IgM-/IgD- B cells. A summary of transitional B cell 
phenotypes before and after IL-4/IL-4 + R848 stimulation is shown in Figure 4, inset 
Table. 
 
Culture with IL-4 or IL-4 plus R848 consistently resulted in subpopulations of R123- B 
cells expressing high, intermediate, and no CD23, respectively (Figure 4B-C, orange). 
An analysis of the R123- cells relative to CD23 expression provided further insight into 
these phenotypes. R848 + IL-4 induced more CD23hi expression than IL-4 alone.  
Under both culture conditions, the majority of CD23hi cells were both IgD and IgM high 
(Supplementary Figure 1). In contrast, the CD23- population was mostly IgMhi IgDhi with 
small subpopulations of IgM+ IgDlo/- and IgM- IgD- cells. These R123- CD23- B cells are 
presumably mature naïve B cells that have downregulated their IgM or IgD B cell 
receptors. Similar to the small population of IgM+ IgDlo/- we observed, recent literature 
suggested that another mature B cell population develops in parallel to Fo B cells that 
are IgM+ IgDlo/- (39). CD23 has been shown to negatively regulate BCR-mediated 
activation and is downregulated in isotype switched B cells (40). Additionally, TLR7 and 
IL-4 stimulation have been shown to induce isotype class switching in activated murine 
B cells (41). Therefore, the small subpopulation of IgM- IgD- cells observed in the R123- 
CD23- population may be isotype switched. 
 
The strong induction of ABCB1 in R848 + IL-4 cultures, along with high CD23 
expression indicated that the combination of IL-4R and TLR7/8 signaling were potent 
   
 
   
 
59 
drivers of transitional B cell maturation. While CD23 expression is generally associated 
with Fo B cells, another population of B cells which express CD23 along with high levels 
of IgM and IgD are marginal zone precursor cells (42, 43). Our stimulated cells that 
have effluxed R123 due to the acquisition of ABCB1 resemble the previously described 
human splenic MZP population (44). However, to identify true MZP cells in our system 
additional analysis is needed to determine if these cells are capable of further MZ 
maturation. Thus, it is not possible to distinguish whether maturing transitional B cells 
under these stimulation conditions represent differentiation along the follicular versus 
the marginal zone B cell lineages. Interestingly, previous literature has supported the 
ability of FO B cells to develop into CD23hi CD21+ MZP cells and vice versa (42). 
 
3.4. IL-4 is necessary for transitional B cell maturation in the presence of TLR9 ligand 
and BCR engagement 
Transitional B cells are highly sensitive to BCR-mediated apoptosis and this stage of 
development is thought to represent a checkpoint for deletion of self-reactive clones that 
migrate to the periphery (27, 45, 46). However, it has been shown that IL-4 can exert a 
protective effect against BCR-mediated apoptosis for murine bone marrow-derived 
immature and transitional B cells (28, 38). Additionally, previous data describes BCR 
engagement as a metabolic activation signal that requires a second signal, either CD40 
or PRR stimulus, to maintain survival and prevent apoptosis (47). Since IL-4 alone as 
well as IL-4 + CpG induced a portion of human cord blood transitional B cells to mature 
into CD23hi Fo-like B cells (Figure 3G) and CpG may serve as a second signal for B 
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cells, we next examined whether these stimuli were capable of overcoming the negative 
effect of BCR engagement on transitional B cells. Transitional B cells were isolated from 
human cord blood and cultured for 48 hours with IL-4 and/or CpG in the presence or 
absence of anti-IgM at various concentrations (Figure 5). CpG treatment alone resulted 
in recovery of a low level of CD23+ B cells (2.76%), however the addition of anti-IgM to 
CpG-containing cultures resulted in the inhibition the development of CD23+ B cells 
(Figure 5) although cell viability was maintained (data not shown), indicating CpG may 
act as a second signal to BCR engagement to promote survival but not maturation of 
transitional B cells. In contrast, cultures containing IL-4 displayed a trend of dose-
dependent increase in frequency of CD23+ cells with anti-IgM treatment (Figure 5). This 
indicated that IL-4 is capable of protecting transitional B cells from the apoptotic effects 
of BCR engagement and IL-4 may instead work as a second signal that confirms BCR 
signaling as an activating signal for B cell maturation. When all three stimuli were 
provided (Figure 5), the frequency of CD23+ B cells reached maximal levels at even the 
lowest anti-IgM dose, suggesting a synergistic effect of BCR, IL-4, and TLR9 ligation on 
transitional B cell maturation. 
 
3.5. Comparison of transitional and follicular B cell transcriptomes 
Due to the limited markers associated with follicular B cell maturation and overlapping 
phenotypes among maturing and mature subsets, it was of interest to define novel 
markers that distinguish transitional and follicular B cell populations. These markers 
could be used to confirm whether our conditions for in vitro stimulation with PRR ligands 
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resulted in the generation of fully mature naive B cells. Transcriptional analysis of 
murine transitional and follicular B cell populations indicated that each have distinct 
gene expression profiles (48, 49). However, limited transcriptional data are available for 
isolated human B cell subsets (50). We performed AmpliSeq analysis on sorted 
transitional B cells from human cord blood and on follicular B cells from human tonsils to 
characterize the transcriptome of human transitional and follicular B cells. Transitional B 
cells (CD3- CD19+ CD24+ CD38+ R123hi) (Figure 2A) and naive follicular B cells (CD3- 
CD19+ CD23+ IgD+) (Figure 2B) were isolated by flow cytometry with >99% purity. 
20,000 unique human transcripts were queried and compared between transitional and 
follicular B cell subsets. RNASeq analysis indicated that 208 transcripts were 
upregulated, while 618 transcripts were downregulated in the follicular B cell subset 
compared to the transitional B cell subset (Figure 6A). The top 20 up and down 
regulated genes in human tonsil follicular B cells compared with human cord blood 
transitional B cells are shown in Table 2. Select genes differentially expressed in Fo and 
transitional B cells were confirmed by real-time qPCR (Figure 6B). 
 
The top upregulated genes in Fo B cells included genes associated with cell cycle 
regulation (CCND1, HJURP), cytoskeletal organization and cell migration (FMNL3, 
LIMA1), cholesterol biosynthesis and metabolism (DHCR24, TTC39B), nucleotide 
metabolism (NT5E/CD73), and receptor and vesicle transport (RAB33A, NR3C2). 
Among the mostly highly-upregulated genes for Fo B cells as compared to transitional B 
cells were two long intergenic non-coding RNA (lincRNA) genes, AC022182.2 (also 
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known as ENSG00000254802) and LINC00643. LincRNAs are a subset of long non-
coding RNAs (lncRNAs). Expression of several lncRNAs have been reported during B-
cell development and maturation (51), and it has been noted that more lncRNAs were 
differentially expressed between B cell subpopulations than protein-encoding genes 
(52), making these potential markers for B cell developmental subsets.   
Among the genes highly upregulated in transitional B cells were four transcription 
factors (NR4A3, FOSL2, NR4A2, and TP531NP2), two genes that regulate apoptosis 
(HRK, NR4A1), genes associated with the extracellular matrix (MMP7, COL1A1), and 
genes involved in the response to extracellular signals (PDE4A, BSIAP3, LDLRAD4).    
Another highly-expressed gene in transitional B cells was the cytokine CSF1 which 
regulates cell migration and cell adhesion.  S1PR1, required for migration of immature B 
cells from bone marrow to blood (53) was highly expressed in both transitional and 
follicular B cells. 
 
Several of the genes expressed in human transitional and follicular B cells have been 
previously reported in the B cell literature. In the current study, ADAM28 was 
upregulated in tonsil Fo B cells relative to cord blood transitional B cells (Table 2).  Data 
from the mouse model has cited a role of ADAM28 in the maturation of murine MZ 
precursors (MZP) to MZ B cells (43), however its expression in human B cells was not 
previously reported. ADAM28-positive Fo B cells may be poised to become MZPs, 
supporting the hypothesized plastic nature of Fo and MZ B cells during B cell 
development (54).  
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Pathway analysis examining transcription of genes associated with BCR signaling, PKA 
signaling, IL-6 signaling, and cyclins & cell cycle regulation found the Fo B cell 
population to be mostly downregulated in comparison to transitional B cells (Figure 7A-
C). Since Fo B cells are resting, naïve B cells that have yet to encounter antigen and 
receive cognate signals from T cells, they may not be as transcriptionally active as the 
less mature transitional B cell population.  Nevertheless, certain genes of these 
pathways were more highly expressed in the Fo B cell population including PTPN6 and 
CD19 involved in BCR signaling and TGFB3 involved in Protein Kinase A signaling 
(Figure 7A, B). The PTPN6 gene encodes for Shp-1, a well characterized tyrosine 
phosphatase that acts to negatively regulate BCR phosphorylation activity in resting 
cells (55). B cell-specific PTPN6-deficient mice have an increased B1a population and a 
decreased B2 population (56), indicating that PTPN6 may play an important role in the 
B2 cell fate decision. The observed upregulation of PTPN6/Shp-1 protein tyrosine 
phosphatase in human FO B cells likely aids in their differentiation and maintenance in 
a resting state until antigen encounter. The CD19 gene encodes for a transmembrane 
glycoprotein expressed on all B cells from pro-B to terminal differentiation into plasma 
cells. CD19 is a critical molecule responsible for proper BCR signaling, adaptor protein 
recruitment, and BCR-independent signaling via the CD19/CD21 complex (57). We 
observed higher CD19 expression on tonsil FO B cells as compared to cord blood 
transitional B cells (Figure 7). The TGFB3 gene encodes for TGF-B3, a pleiotropic 
cytokine known to suppress murine and human B cell antibody production and 
proliferation (58). In addition to the role of TGF-B3 in B cell function, resting B cells 
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secrete TGF-B3 which can expand the regulatory T cell population (59). As Fo B cells 
are in a resting state, it is likely that they secrete TGF-B3 until antigen encounter or 
activation via other external stimuli.   
 
B cell maturation and function are highly regulated by members of the TNFR (tumor 
necrosis factor receptor) superfamily (60). Our transcriptome analysis revealed 
differential expression of many TNFR superfamily genes (Figure 8). While expression 
for certain of these genes showed variation between samples, several TNFR 
superfamily members were consistently up- or down-regulated for all three samples. 
TNFRSF17, encoding the B cell maturation antigen (BCMA), was one of the 
consistently upregulated genes in Fo B cells. BCMA is a receptor that binds both BAFF 
and APRIL, key cytokines involved in normal B cell development. While previously 
literature indicates that BCMA is not required for normal B cell maturation (61), it is 
plausible that BCMA expression contributes to Fo B cells development and activation. 
 
Our analysis demonstrates an upregulation of RANKL transcripts on tonsil FO B cells 
and an upregulation of RANK transcripts on cord blood transitional B cells (Figure 8). 
The RANKL/RANK (Receptor activator of NF-kB (ligand) signaling pathway plays a key 
role in bone homeostasis and lymphoid tissue development (62). Membrane-bound and 
soluble RANKL (TNFSF12) is produced by several lymphoid cells including activated B 
cells and has been shown to drive osteoclast maturation. RANK (TNFRSF11A) was 
originally described on dendritic cells, but since then has been described on B cells. 
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Additionally, mouse studies have shown that RANK-deficiency leads to abnormal B cell 
development and decreased mature B cell counts in the periphery. Since FO B cells are 
a recirculating B cell subset, it is likely that their RANKL production is in support of 
normal bone homeostasis. Transitional B cell RANK transcription supports the notion 
that B cells require RANK for complete maturation and migration in the periphery.  
 
3.6. CpG + IL-4 and CpG alone induce differential gene expression in transitional B cells 
Our AmpliSeq analysis of human cord blood transitional B cells and human tonsil 
follicular B cells identified several differentially expressed genes. We chose to 
investigate six genes as potential markers of Fo B cell differentiation: FCER2, PTPN6, 
ADAM28, PRDM1, and CD27 (Figure 9). FCER2 encodes for CD23, a known follicular 
B cell marker which was used as a key surface marker for B cell maturation in our 
studies. In accordance with our previous results, we find that transitional B cells 
stimulated with CpG + IL-4 express higher levels of FCER2 than CpG-stimulated 
transitional B cells. PTPN6 expression was found to be upregulated in purified human 
tonsil Fo B cells as compared to transitional B cells (Figure 7). CpG-stimulated 
transitional B cells expressed PTPN6, while CpG + IL-4 stimulation did not induce 
PTPN6 expression. Interestingly, we observed increased ADAM28, PRDM1, and CD27 
expression in transitional B cells stimulated with either CpG + IL-4 or CpG alone. Our 
AmpliSeq results showed that ADAM28 was upregulated in Fo B cells as compared to 
transitional B cells. Since we observe ADAM28 expression following both stimulation 
conditions, it is likely that ADAM28 is a general marker of transitional B cell maturation. 
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PRDM1 and CD27 were upregulated in both of our stimulation conditions. PRDM1 
encodes for BLIMP-1, a transcriptional regulator involved in plasma cell differentiation, 
and CD27 is a marker for both memory B cells and human MZ B cells. PRDM1 and 
CD27 gene expression in transitional B cells stimulated with CpG + IL-4 or CpG alone 
suggested that these cells are on a path to terminally differentiate. Additionally, culture 
conditions that induce CD27 expression may indicate some MZ-like B cell development. 
 
4. Discussion 
PRR ligands occur as pathogen components and endogenous host products (21, 23, 
63, 64) and are of particular interest as vaccine adjuvants (65). PRR ligands can 
qualitatively shape the resulting immune response, inducing B cell activation, 
proliferation and expansion of the antibody repertoire (66-68).  
 
The first part of this study examined the direct effect of PRR ligands on human 
transitional B cell maturation, focusing on the maturation along the follicular (Fo) 
pathway. Our study tested the effects of ligands of six PRRs: TLR3, TLR4, TLR7, TLR9, 
NOD1, and the C-type lectin receptor, Mincle. While there currently is no clear 
consensus of PRR expression by human B cells, in general, TLR7 and TLR9 have been 
detected in cord blood and peripheral blood B cells while TLR3 and TLR4 have low to 
no expression (12, 69-73). NOD1 has been identified on mixed populations of tonsillar B 
cells (74), however its expression on individual B cell subpopulations and at various 
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developmental stages has not been determined. Mincle is present in peripheral B cells 
(75), but its expression in transitional B cells has not been previously investigated.  
 
In a series of experiments using human cord blood as a source of transitional B cells, 
we found that TLR7, TLR9, or NOD1 ligation in the presence of IL-4 are particularly 
effective in driving transitional B cell maturation as measured by CD23 expression and 
ABCB1 activity as measured by R123 extrusion. The majority of transitional B cells 
stimulated with these PRR ligands matured into ABCB1+, CD23hi B cells expressing 
high levels of sIgM and sIgD. Our results expands upon a previous report that TLR9 
ligation can preferentially drive the differentiation of human transitional B cells into 
mature B cells (20), a capability apparently shared by only a few other PAMPS. Since 
our in vitro cultures consisted of purified cell populations, our study further demonstrates 
that human cord blood transitional B cells express functional TLR7, TLR9, and NOD1.  
 
In mice, TLR4 agonists can promote B cell maturation as measured by CD23 and sIgD 
expression (76).  In our in vitro cultures, ligands for TLR3 and TLR4 in the presence of 
IL-4 did not have a significant effect on human transitional B cell maturation, reflecting a 
lack of TLR3/TLR4 expression and/or function in these cells.  Our data are consistent 
with other studies suggesting that human B cells express low levels of TLR3 and TLR4 
(77). While, it has been reported that IL-4 induces TLR4 expression on human 
peripheral B cells (78), this did not appear to be the case for cord blood transitional B 
cells stimulated with IL-4.  
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The Mincle ligand TDB plus IL-4 inhibited CD23+ B cell maturation while slightly 
increasing expression of CD21 and FcRL4 (data not shown) in the CD23- population, 
suggesting delayed maturation or maturation along the marginal zone pathway by this 
PRR. The distinct response of transitional B cells to TDB supports the concept that 
differentiation induced by Mincle may involve a signaling pathway not shared with TLR7, 
TLR9 or NOD1. Mincle and other C-type lectin receptors signal through FcRJ/Syk and 
have been shown to induce gene expression independent of other PRR signaling (79). 
We propose that transitional B cell maturation can be achieved by TLR7, TLR9, and 
NOD1 stimulation, however, our data could not discriminate whether these maturing B 
cells were differentiating along the Fo or MZ pathways.  
 
The TLR9 ligand CpG was the only PAMP capable of preserving transitional B cell 
viability in the absence of IL-4, and it had strikingly different effects on transitional B cell 
maturation depending on the cytokine environment. In the presence of IL-4, CpG 
induced B cells to mature and express high levels of CD23 consistent with Fo B cell 
differentiation. However, in the absence of IL-4, CpG-stimulated the majority of 
transitional B cell cultures to express intermediate levels of CD23 more consistent with 
the T2 transitional stage (29). Our results contrast with another study, which reported 
MZ, rather than Fo, B cell differentiation of transitional B cells stimulated by CpG (20). 
Since this previous study did not supplement their cultures with IL-4, our results suggest 
that the presence of specific cytokines in the microenvironment of developing B cells 
can dramatically influence their differentiation. IL-4 is a pleiotropic cytokine shown to be 
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necessary to maintain the viability of human transitional B cells in vitro (31, 38). We 
observed the viability of B cells in our in vitro cultures supplemented with IL-4 to be 15-
fold higher than cultures without IL-4 (data not shown). In addition to its anti-apoptotic 
effect, we found that IL-4 contributes to B cell maturation as measured by CD23 
expression and inhibits BCR-induced apoptosis. Our in vitro data are consistent with 
previous studies in the mouse, which demonstrated that IL-4 protected transitional B 
cells from apoptosis and supported their maturation to CD23+ cells (38).  
 
In addition to CD23, we analyzed R123 retention to track in vitro transitional B cell 
maturation. Three populations with different levels of R123 were detected following 
culture with IL-4 with or without PRR ligands: R123hi, transitional B cells, R123int, 
maturing B cells, and R123neg, fully, mature B cells. R123hi and R123int B cells 
represented the majority populations found in cord blood B cells prior to culture. At the 
end of culture, a prominent R123neg population was detected. CD23, CD21, IgM, and 
IgD expression were analyzed in all three R123 populations to add to our understanding 
of how surface marker expression changed as transitional B cell maturation progressed. 
Of note, the CD23 expression and upregulation of surface IgD and IgM were observed 
prior to R123 extrusion, indicating that these events precede ABCB1 expression in the 
stepwise progression of B cell maturation. Furthermore, the fully, mature R123neg B cell 
population contained two subpopulations, a majority population of R123neg CD23hi B 
cells and a minority population of R123neg CD23neg B cells.   IL-4 alone cultures included 
a larger proportion of R123negCD23neg B cells than R848 + IL-4 cultures. The 
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observation that R123hi, R123int, and R123neg populations are mostly IgMhi and IgDhi 
following both culture conditions, indicated that IL-4 and/or R848 are potent inducers of 
IgM and IgD expression, hallmarks of mature, naïve B cells. Examination of R123 
retention complimented our previous in vitro transitional B cell studies focusing on CD23 
acquisition and provided further insight into the step-wise process of B cell maturation.  
 
In the second phase of our studies, we examined the synergistic effect of IL-4 and PRR 
stimulation as well as B cell receptor stimulation on transitional B cell maturation. 
Human transitional B cell cultures containing IL-4 and anti-IgM displayed a trend of 
concentration-dependent increase in CD23+ cells. Therefore, in addition to inhibiting 
BCR-mediated apoptosis in transitional B cells, IL-4 appeared to serve as a second 
signal along with BCR engagement for promotion of B cell survival and maturation. If 
the BCR stimulus by itself is considered to mimic central tolerance of transitional B cells, 
our findings demonstrate that IL-4 can overcome this negative selection, possibly by 
inhibiting Fas-mediated apoptosis similar to BAFF (80). CpG alone prevented cell death 
in BCR-stimulated cells but could not fully induce transitional B cell maturation as 
measured by only partial expression of the CD23hi phenotype (Figure 3H), indicating 
that TLR9 signaling may be sufficient for cell survival, but insufficient to drive complete 
transitional B cell maturation. 
 
The third part of this study examined the transcriptomic profiles of human cord blood 
transitional B cells and tonsil follicular B cells. Our study compared human transitional 
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and follicular B cell subsets as a means to identify select genes associated with the 
complete maturation of transitional B cells to a follicular phenotype. Pathway analysis 
found the Fo B cell population to be transcriptionally quiescent relative to transitional B 
cells, with the exception of select genes involved in BCR signaling, PKA signaling, and 
the TNFR superfamily. In contrast, transitional B cells had higher variation of gene 
expression between samples and higher expression of genes involved in IL-6 and IL-4 
signaling, and NF-kB signaling. Further analysis found several genes to be uniquely 
expressed in either follicular or transitional B cells. Transitional B cells, the precursor 
population to follicular B cells, contain many differentially expressed genes most likely 
linked to their stage of development where they are poised for maturation and migration 
to secondary lymphoid tissue. Harakiri (HRK) has been previously identified as an 
apoptosis regulatory gene whose gene product interacts with Bcl-2 to induce cell death 
(81). We observed approximately 6-fold higher HRK expression in transitional B cells 
than in follicular B cells. HRK may play a role in transitional B cells which are poised to 
undergo apoptosis in the absence of appropriate survival signals. When peripheral 
CD24hi CD38hi transitional B cells were compared to the maturing CD24+ CD38+ and 
fully mature CD24+ CD38-, HRK gene expression was highly upregulated (82), 
consistent with the observations of the current study. Additionally, we observed FOSL2 
expression to be preferentially elevated in the transitional B cell population. FOSL2 is a 
subunit of the AP-1 transcription factor, which regulates B cell proliferation and 
differentiation via genes essential for early B cell development including Foxo1, Irf4, and 
Aiolos (83). Previous literature has implicated Aiolos as an important gene in the 
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follicular or marginal zone B cell fate decision (84). The elevated level of FOSL2 in 
transitional B cells aligns with the role of these cells as precursors for the mature 
follicular or marginal zone B cell subsets. 
 
Following transitional B cell migration to secondary lymphoid organs, a fraction will 
differentiate into follicular B cells. Transcriptome analysis of tonsil follicular B cells 
identified several genes that may be important in the maturation and maintenance of 
this population. Previous work in the mouse model has demonstrated that CD19 is 
necessary for B cell survival and maintenance of the peripheral B cell pool (85). 
Interestingly, B cell-specific CD19 deficiencies disrupt the Fo and MZ populations, while 
the transitional B cell population remains intact. The increased CD19 expression found 
on human tonsil Fo B cells is consistent with the importance of CD19 in mature B cells. 
Elevated expression of ADAM28 in the Fo B cell population was surprising as previous 
literature has linked ADAM28 expression to the murine MZ precursor population. 
However, others have hypothesized that the Fo B cell population may be able to 
differentiate into MZ B cells. Additionally, our data showing the R123lo maturing B cells 
express CD23 suggest that a CD23+ population may give rise to a mature R123- CD23- 
MZ population. Therefore, it is plausible that ADAM28 expression on CD23+ B cells 
denotes a population capable of MZ B cell differentiation. The mechanism with which 
this occurs has yet to be defined.  
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PTPN6 and TNFRSF17 (BCMA) are both important genes involved in signaling and 
maintenance of the follicular B cell population. PTPN6 negatively regulates BCR 
signaling and likely aids in the maintenance of a resting follicular B cell population. 
BCMA, although previously noted to be indispensable for B cell development, likely 
contributes to follicular B cell development as a BAFF receptor, a key cytokine in B cell 
development.  
 
The transcriptional analysis of human transitional and follicular B cell subsets has 
allowed for the identification of genes unique to their respective subsets. We found HRK 
and FOSL2 are transitional B cell-specific, while PTPN6, BCMA, and ADAM28 are 
follicular B cell-specific. Future studies are needed to determine whether these genes 
are consistent in transitional and follicular B cells from other cell sources. In our brief 
analysis of gene expression from stimulated transitional B cells, we observe that select 
genes associated with follicular B cell maturation are expressed. Additional studies are 
required to establish a complete panel of follicular B cell-associated maturation genes.  
 
As recent bone marrow emigrants, transitional B cells are the earliest circulating B-
lineage cells to encounter antigen resulting from infection or vaccination. The effect of 
the adjuvant constituent of a vaccine on transitional B cells is of particular interest 
because it can qualitatively alter the resulting immune response, particularly in children 
who have a higher level of circulating transitional B cells (86) than adults. Previous 
literature focused on naïve and memory B cell responses to immune modulators like 
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PRR ligands (66, 71, 87-90). However, transitional B cell maturation during an immune 
response contributes to the B cell population capable of participating in the adaptive 
immune response. It is critical that the B cell repertoire, in the context of infection or 
vaccination, contain clones sufficiently diverse enough to recognize different pathogen 
variants and PRR stimulation of transitional B cell maturation may broaden the resulting 
mature B cell repertoire. A dual control system for transitional B cell maturation has 
been proposed (91) suggesting that BCR/BAFFR signaling cooperate to produce a B 
cell repertoire with diverse BCR affinities. Our in vitro model suggests that IL-4 and PRR 
signaling may behave similarly to BAFFR signaling in this dual control system by 
expanding the B cell repertoire in an antigen-independent manner. 
 
Our current studies indicate that transitional and follicular B cells have unique gene 
expression patterns and transitional B cell maturation may be influenced by several 
environmental cues including IL-4, PRR ligands, and BCR engagement. We propose 
that these signals work concurrently to create a balanced mature B cell repertoire 
necessary for a robust and efficient adaptive immune response. Further studies are 
needed to evaluate the impact of PRR- and IL-4-dependent, antigen-independent 
signaling on the B cell repertoire, as well as to define how PRR ligands, specifically in 
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Figure 1. Transitional B cells from human cord blood and peripheral blood 
mononuclear cells. Cryopreserved cord blood mononuclear cells were thawed and 
transitional B cells were FACS-sorted based on expression of surface markers, CD19, 
CD24, CD38 and the presence of Rhodamine 123. Total cells were gated based on 
lymphocyte morphology, followed by gates on viable CD19+ CD3- cells, and finally 
R123hi
R123lo
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Rhodamine 123 fluorescence (A). Expression of IgD, CD21, CD23, CD5, and IgM are 
shown as histogram plots for high and low Rhodamine 123 expression (B). Freshly 
isolated PBMCs were labeled with fluorochrome-conjugated antibodies against the 
surface markers, CD19, CD24, CD38, CD21, CD23, IgD, and IgM. Total cells were 
gated based on lymphocyte morphology, followed by viable CD19+ cells, and CD38hi 
CD24hi expression. Expression of CD21, CD23, IgD and IgM are shown as histogram 























Figure 2. Sorting strategies for human cord blood transitional B cells and human 
tonsil follicular B cells. Cord blood mononuclear cells were stained with Rhodamine 
123 and chased for 3 hours. Following R123 pulse/chase, cells were stained with 
fluorochrome-conjugated antibodies against CD3, CD19, CD24, and CD38. Transitional 
B cells were sorted based on high R123 expression following the initial gating strategy 
(A). Tonsil mononuclear cells were isolated from fresh tonsil tissue via mechanical 
homogenization and Ficoll density gradient centrifugation. Cell suspensions were 
stained with fluorochrome-conjugated antibodies against CD3, CD19, CD23, IgD, IgM. 







Figure 3. Transitional B cell differentiation into marginal zone-like or follicular-like 
phenotypes. FACS-sorted transitional B cells were cultured with IL-4 and individual 
PRR ligands as denoted at 5x105 cells/mL for 2 days. The expression of CD23 and 
R123 retention was evaluated to determine whether transitional B cells had matured. 
R123 negative, CD23+ cells were considered mature FO-like B cells. The highest 
percentage of transitional B cells driven to a Fo-like B cell phenotype were stimulated 
with R848 (B), iE-DAP (C), and CpG (G) in the presence of IL-4. The proportion of 
CD23+ cells after stimulation with GLA (D) or Poly(I:C) (E) was comparable to 
unstimulated cultures (A). A population of CD23hi cells was detected in all cultures with 
A B C D
E F G H
I J K
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the highest percentages resulting from R848 and CpG stimulations in the presence of 
IL-4. A small proportion of cells stimulated with TDB (F) and CpG (H) alone 
differentiated into a CD23- CD21+ population. Data shown are representative of four 
independent experiments. Statistical significance was determined using Student’s t test 
for plots showing % CD23 high (I), CD23 MFI (J), % CD23- CD21+ (K) for combined 












Figure 4. R123 expression highlights three distinct populations of immature 
transitional, maturing transitional, and mature B cells. Baseline CD23, CD21, and 
IgD expression on FACS-sorted transitional B cells was similar for R123lo and R123hi 
cord blood B cells (A). IgM expression on R123hi (red histogram) cells was mostly high, 
while IgM expression on R123lo (blue histogram) cells was more heterogeneous. FACS-
sorted transitional B cells were cultured with IL-4 and IL-4 + R848 at 5x105 cells/mL for 
2 days. R123hi (red histogram), R123lo (blue histogram), R123- (orange histogram) 
expression following stimulation with IL-4 (B) is more varied than IL-4 + R848 stimulated 
cells’ R123 expression (C). Table 1 summarizes the surface phenotypes for R123hi, 












































































**CD23 expression in R123int B cells is highest in cells 
stimulated with both IL-4 and R848
*CD23neg minority mature B cell population is more prominent 
in IL-4 cultures than in cultures stimulated with both IL-4 and 
R848
Table 1. Human cord blood transitional B cell population 
phenotypes before and after IL-4/IL-4+R848 stimulation
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Figure 5.  IL-4 is necessary for B cell maturation in the presence of BCR 
engagement. FACS-sorted transitional B cells were cultured with IL-4 and CpG 
individually or in combination and with varying concentrations (low-2ug/mL, medium-
10ug/mL, high-20ug/mL) of anti-human IgM/IgG at 5x105 cells/mL for 2 days. In the 
presence of IL-4, the frequency of CD23+ cells increased with BCR engagement in a 
dose-dependent manner (A). However, when stimulated with CpG plus IL-4, the 
frequency of CD23+ cells increased with BCR engagement in a dose-independent 
manner (B). In contrast, in the absence of IL-4, transitional B cells do not mature into 
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Figure 6. Transcriptome analysis of tonsil follicular B cells and cord blood 
transitional B cells. Mean differences plot (A) showing the gene expression fold 
change. Statistically significant differences in gene expression between tonsil follicular B 
cells and cord blood transitional B cells are in red. The top 20 upregulated and 
downregulated genes in tonsil follicular B cells as compared to cord blood transitional B 
cells are listed in Table 2. RT-qPCR confirmation of select genes identified from the 



























Figure 7. Pathway analysis of tonsil follicular B cells and cord blood transitional 
B cells. Heatmap display of cell populations from three individuals. Pathways analyzed 
were IL-6 signaling, NF-kB signaling, PKA signaling (A); BCR signaling, Cyclins & Cell 
Cycle Regulation, Th1/Th2 activation (B); IL-4 signaling, Notch signaling, PI3K signaling 




Figure 7. Pathway analysis of tonsil follicular B cells and cord blood transitional 
B cells. Heatmap display of cell populations from three individuals. Pathways analyzed 
were IL-6 signaling, NF-kB signaling, PKA signaling (A); BCR signaling, Cyclins & Cell 
Cycle Regulation, Th1/Th2 activation (B); IL-4 signaling, Notch signaling, PI3K signaling 




Figure 7. Pathway analysis of tonsil follicular B cells and cord blood transitional 
B cells. Heatmap display of cell populations from three individuals. Pathways analyzed 
were IL-6 signaling, NF-kB signaling, PKA signaling (A); BCR signaling, Cyclins & Cell 
Cycle Regulation, Th1/Th2 activation (B); IL-4 signaling, Notch signaling, PI3K signaling 













Figure 8. TNFR superfamily transcriptome analysis of tonsil follicular B cells and 
cord blood transitional B cells. Heatmap display of cell populations from three 
individuals. Transitional B cells from individual T3 show higher expression of TNFR 






























Gene Synonyms Functions log2FoldChange pvalue padj
TNFAIP8L2 TIPE2
negative regulator of TLR and TCR function; 
prevents hyperresponsiveness and maintains 
homeostasis 2.477275461 6.09E-09 1.29E-07
TNFSF12 APO3L, DR3LG, TNLG4A, TWEAK induces apoptosis 2.240205889 4.92E-05 0.00038221
TNFSF11
CD254, ODF, OPGL, OPTB2, RANKL, TNLG6B, 
TRANCE, hRANKL2, sOdf regulation of apoptosis 2.183612636 9.10E-07 1.16E-05
TNFSF10 APO2L, CD253, TL2, TNLG6A, TRAIL apoptosis inducer 2.133541862 0.00062152 0.003359
TNFRSF17 BCM, BCMA, CD269, TNFRSF13A major receptor for BAFF and APRIL 2.119996653 2.36E-06 2.67E-05
TNFRSF14-AS1 non-coding RNA 1.362625355 0.00077121 0.00403963
TNFSF4 CD134L, CD252, GP34, OX40L, TNLG2B, TXGP1
ligand for OX40 (expressed mainly on CD4 T 
cells); supports Th responses 1.171293841 0.02875562 0.08102038
TNFRSF1B TNFBR, TNFR80, CD120b -1.246213512 0.0001521 0.00101432
TNFAIP6 TSG6 -1.503277925 0.00058692 0.00319843
TNFAIP2 B94, EXOC3L3 -1.580776611 0.00527552 0.02022736
TNFRSF25
APO3, DR3, GEF720, LARD, PLEKHG5, TNFRSF12, 
TR3, TRAMP, WSL-1
unkown function in B cells; enhances 
proliferation in CD4 T cells -1.682814055 0.0053673 0.0205309
TNFRSF9 4-1BB, CD137, ILA
expressed on CD40 stimulated B cells; 
promotes survival via non-canonical NFkB 
activation in CLL B cells -1.946836193 0.00123681 0.0060399
TNFRSF1A CD120a, FPF, TBP1, TNF-R, p55, p55-R, p60 -1.993570983 0.00026115 0.00161475
TNFRSF11A RANK, CD265, FEO, ODFR, OPTB7, TRANCER
receptor activator of NFkB; essential mediator 
for lymph node development -2.041163282 0.00210877 0.0094482
TNFRSF4 OX40, ACT35, CD134, IMD16, TXGP1L suppresses apoptosis by inducing BCL2 -2.318292277 5.67E-05 0.00042968
TNFRSF12A CD266, FN14, TWEAKR -2.631644263 4.50E-07 6.26E-06
TNFSF9 4-1BB-L, CD137L, TNLG5A T cell costimulatory molecule -2.77999548 1.06E-05 0.00010098
TNFRSF21 BM-018, CD358, DR6 death receptor 6; induces apoptosis -4.124865634 1.17E-18 1.08E-16
TNFAIP3 A20, AISBL, OTUD7C, TNFA1P2
inhibits NFkB activation and TNF-mediated 
apoptosis -4.252352143 1.39E-50 1.99E-47


















































































Figure 9. Gene expression analysis of transitional B cells stimulated with  
CpG + IL-4 or CpG alone. Total RNA from stimulated transitional B cells was isolated 
and converted to cDNA. FCER2 (CD23), PTPN6 (Shp-1), ADAM28, PRDM1 (Blimp), 
and CD27 primers with cDNA template and SYBR Green Supermix were used for real-
time qPCR reactions. Gene expression fold change was calculated using ACTB as the 




Supplemental Figure 1. Phenotypic analysis of FACS-sorted transitional B cells 
stimulated with IL-4 or IL-4 + R848. FACS-sorted transitional B cells were cultured 
with IL-4 and IL-4 + R848 at 5x105 cells/mL for 2 days. IgM and IgD expression on 
CD23+ and CD23- cells from the R123 negative population following stimulation with IL-
4 and IL-4+R848 were analyzed. IL-4 + R848 stimulation drives more cells to extrude 
R123 and become R123 negative. The phenotypes of R123- cells following IL-4 
stimulation is mostly CD23- with some CD23+. R123- cells following IL-4 + R848 

































During normal B cell development, transitional B cells emigrate from the bone marrow 
and following various stimuli and signaling, differentiate into mature follicular or marginal 
zone B cells in the spleen. Follicular B cells make up the majority of the mature naïve B 
cell pool and are a circulating B cell subset capable of recognizing T cell-dependent 
antigens (1). Following cognate interactions, follicular B cells found the germinal center 
resulting in high-affinity, antibody-producing plasma cells or memory B cells (2). 
Marginal zone (MZ) B cells are a subset of mature B cells originally characterized in the 
marginal zone of mouse spleens. MZ B cells have been implicated as the first line of 
defense against bloodborne pathogens (3) as well as key players in the rapid IgM 
response to infection and vaccination (4). While MZ B cells are well-defined in the 
mouse, they are less defined in the human. 
 
In the mouse, MZ B cells are distinct from follicular and B1 cells with the following 
phenotype: CD19+ IgMhi IgDlo CD21hi CD23- CD1dhi (5).  Murine MZ B cells only occupy 
the marginal zone of the spleen and do not circulate in the periphery. Additionally, 
murine MZ B cells primarily express non-mutated IgV genes which results in 
promiscuous antibody reactivity (3, 6). Other characteristics of murine MZ B cells 
include high expression of Toll-like receptors (TLRs), MHC class II, CD80 and CD86, as 
well as the ability to respond to T cell-dependent and T cell-independent antigens with 
low affinity antibody (4, 7-9).  
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The human splenic marginal zone contains B cells with similar phenotypic and 
functional characteristics to murine MZ B cells and are considered the human splenic 
equivalent (5). In humans, the spleen is not the only tissue containing MZ B cell 
equivalents. Human MZ B cell equivalents are found in various tissues including the 
subcapsular sinus of lymph nodes, epithelium of tonsillar crypts, and the subepithelial 
dome of Peyer’s patches (10-12). However, with the exception of being uniformly 
IgM+CD23-/lo, these B cells have varying cell surface phenotypes (Table 1).  
 
Cell location Cell phenotype References 
Splenic marginal zone IgM+ IgD- CD23- CD21+ CD35+ (10) 
FcRL4+/- CD21+ CD27+ BCL2+ CD45RA- (13) 
Lymph nodes IgM+ CD25+ CD5- CD10- CD23- IgDlo/- (11) 
Subepithelial layer of 
tonsils 
IgM+ IgD+ CD23- CD38+/- CD10- CD44+ (14) 
CD19+ CD5- CD21lo CD22+ CD23lo IgM+ IgDlo 
CD27+/- 
(15) 
FcRL4+ CD21+/- CD27+/- BCL2+ CD45RA+ (13) 
Subepithelial dome of 
Peyer’s patches 
 
IgM+ IgD- CD23- CD21+ CD35+ (10) 
Table 1. Cell surface marker phenotype of human marginal zone B cell 
equivalents from different locations. Uniform CD23-/lo and IgM+ expression is bolded. 
 
This manuscript characterizes the phenotype and gene expression of the CD23- 
population in human tonsils and investigates the potential for PRR ligands to drive 
transitional B cells to mature into CD23- B cells. Previous literature suggests that the 
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CD23- B cell population contains MZ B cells, IgM memory B cells, and switched memory 
B cells (16). IgM memory and switched memory B cells have encountered antigen and 
developed in a GC-dependent or GC-independent manner (17). It is unlikely that our in 
vitro system can support the development of IgM memory and switched memory B cells. 
Therefore, transitional B cells that mature in vitro into CD23- B cells should contain MZ-
like naïve B cells. 
 
2. Materials and Methods 
2.1. FACS isolation of B cell subsets 
Cryopreserved human cord blood mononuclear cells were obtained from Hemacare 
(Van Nuys, CA), Lonza (Alpharetta, GA), and STEMCELL Technologies Inc. 
(Vancouver, BC) and used as a source of transitional B cells. Human tonsils were 
obtained following routine tonsillectomies from the Kapi’olani Medical Center for Women 
and Children, Hawai‘i Pacific Health System (Honolulu, HI) and were used as a source 
of MZ and FO B cells. These studies were reviewed and determined not to be human 
subjects research by the institutional review boards of the University of Hawai‘i and 
Hawai‘i Pacific Health. Freshly isolated tonsils were soaked overnight in Hank’s 
Buffered Saline Solution (HBSS; Thermo Fisher Scientific, Waltham, MA, USA) with 1x 
penicillin-streptomycin. Tonsils were minced and homogenized through a 40 um cell 
strainer. Tonsil mononuclear cells were isolated by density-gradient centrifugation using 
Ficoll-Hypaque (GE Healthcare, Chicago, Il, USA). Mononuclear cells were collected at 
the interphase and washed in 1x HBSS. All cells were resuspended in HBSS with 2% 
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fetal bovine serum for downstream fluorescence-activated cell sorting (FACS) and 
analysis. 
 
2.2. Antibodies and reagents 
The following fluorochrome-conjugated anti-human antibodies and fluorescent dyes 
were used for flow cytometry analyses: CD19-BV605, CD3-BV421, and CD23-BV421 
(BD Biosciences, Franklin Lakes, NJ, USA); IgM-APC (Biolegend, San Diego, CA, 
USA); CD19-eVolve 605, CD38-PE-eFluor 610, CD24-APC-eFluor 780, CD21-PerCP-
eFluor710, FcRL4-PerCP-eFluor 710, IgD-PerCP-eFluor710, CD5-APC, 7AAD, CD86-
PE-Cy7, HLA-DR-Alexa Fluor 647, ICOSL-PE-CF594, Propidium Iodide, Rhodamine 
123 (Thermo Fisher Scientific). Resiquimod (R848) and glucopyranosyl lipid A (GLA) 
were obtained from the Infectious Disease Research Institute (Seattle, WA). C12-iE-
DAP (iE-DAP), polyinosinic-polycytidylic (Poly I:C), trehalose-6,6-dibehenate (TDB), and 
CpG ODN 2006 (CpG) were purchased from InvivoGen (San Diego, CA). 
 
2.3. B cell isolation and culture conditions 
FACS-sorted transitional B cells (CD3- CD19+ Rhodamine123hi CD24+ CD38+) were 
seeded in a 96-well U-bottom plate at 5 x 105 cells/mL in RPMI containing 10% FBS 
and 1x penicillin-streptomycin (Thermo Fisher Scientific). Transitional B cells were 
cultured in medium supplemented with IL-4 (100ng/mL; PeproTech, Rocky Hill, NJ, 
USA), R848 (TLR7/8 ligand; 5ng/uL), GLA (TLR4 ligand; 2ng/uL), CpG ODN 2006 
(TLR9 ligand; 0.25uM), iE-DAP (NOD1 ligand; 2.22ng/uL), TDB (Mincle ligand; 
20ng/uL), or Poly(I:C) (TLR3 ligand; 20ng/uL). After 2 days, B cell cultures were 
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analyzed for CD19+ R123lo CD23- IgM+ FcRL4+ B cell surface markers by flow cytometry 
and total RNA extracted for downstream real-time quantitative PCR. FACS-sorted 
marginal zone-like B cells (CD3- CD19+ CD23- IgM+ FcRL4+) and follicular B cells (CD3- 
CD19+ CD23+ IgD+) were immediately lysed for downstream RNA sequencing. 
 
2.4. Flow cytometry analysis 
Flow cytometry sorting and analyses were performed on a FACSAria instrument (BD 
Biosciences, San Jose, CA) and an Attune NxT instrument (Thermo Fisher Scientific) at 
the Cellular and Molecular Immunology Core Facility at the John A. Burns School of 
Medicine, University of Hawai‘i at Mānoa. Cells were stained with the appropriate 
antibodies and incubated in the dark at 4°C for 30 minutes. Cells were then washed 
twice and resuspended in 1x HBSS supplemented with 2% FBS for sorting and 
analyses. Analyses were performed using FlowJo data analysis software (FlowJo, 
Ashland, OR). 
 
2.5. RNA Sequencing 
Tonsil follicular (CD19+ CD23+ IgD+) and marginal zone B cells (CD19+ CD23- IgM+ 
FcRL4+) were sorted by flow cytometry and total RNA was extracted using the RNeasy 
Mini kit (Qiagen, Germantown, MD). Total RNA was submitted to the Genomics Shared 
Resource at the University of Hawai‘i  Cancer Center for cDNA library preparation and 
sequencing. Total RNA was quantified, and quality checked using the Bioanalyzer RNA 
2100 Pico instrument (Agilent, Santa Clara, CA). Libraries were prepared with 10ng 
RNA using the AmpliSeq for Illumina Transcriptome Human Gene Expression Panel 
 109 
(Illumina, San Diego, CA). Sequencing was performed using a NextSeq 500 DNA 
Sequencer (Illumina, San Diego, CA). Raw FASTQ files were transferred to the 
Bioinformatics core at the John A. Burns School of Medicine, University of Hawai‘i at 
Mānoa for gene expression analysis. Raw reads were processed using CutAdapt (18) 
and aligned to human genome (hg38) using STAR (19). Gene counts were quantified 
using Partek E/M Quantification (Partek Inc., St. Louis, MO). DESeq2 (20) was used to 
analyze differential gene expression and data were visualized using R. Ingenuity 
Pathway Analysis (Qiagen Bioinformatics, Redwood City, CA) was used for pathway 
and network analysis. 
 
2.6. Gene expression analysis 
For real-time quantitative PCR, total RNA was extracted using the RNeasy Mini/Micro 
kit (Qiagen, Germantown, MD). RNA was reverse-transcribed into cDNA using the 
cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA). For Notch signaling 
analysis, cDNA was used directly in PrimePCR assays (Notch signaling pathway plates 
or custom Notch gene plates; Bio-Rad Laboratories). For mature B cell gene expression 
analysis, cDNA was added to SYBR Green Supermix (Bio-Rad Laboratories) and Btk, 
Id2, Id3, Asb2, and Tcf3 primers (Qiagen). All real-time qPCR analyses were run on an 
Applied Biosystems 7500 Real-Time PCR System (Thermo Fisher Scientific). 
 
2.7. Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, San 
Diego, Ca). Unpaired Student’s t tests were employed where appropriate. Data are 
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represented as means +/- SEM. Statistical significance was determined as follows: p > 
0.05 (not significant), *p ≤ 0.05, or **p ≤ 0.01 (significant). 
 
3. Results 
3.1. Tonsil CD23- B Cell Characterization and Activation State 
Tonsils contain CD19+ B cells that express CD21 and moderate to high levels of CD23 
as well as cells that are CD21+/- CD23- (Figure 1).  When these two populations are 
compared, CD23+ cells are IgD+, IgM+ and CD38lo, and are considered to represent Fo 
B cells (Figure 1A).  In contrast, CD23- cells are either negative or positive for CD21, 
include both IgD+ and IgD- cells, are predominantly IgM negative, and include CD38lo as 
well as a few CD38hi populations (Figure 1A). These CD23- cells may include MZ B cells 
as well as IgM memory and switched memory B cells (16). To identify naïve CD23- B 
cells, we characterized IgD+ CD23- tonsil B cells and found that these cells are 
predominantly IgM+ and CD38lo/- (Figure 1A; bottom row), consistent with the MZ B cell 
phenotype. 
 
To characterize basal levels of activation, both CD23+ and CD23- B cells (CD3- CD19+) 
were isolated from tonsils and analyzed for CD86 expression (Figure 1B). CD23- B cells 
had higher levels of CD86 expression than CD23+ B cells, with the majority of CD23- B 
cells being CD86+, similar to previous studies (21). As our CD23- tonsil B cells included 
the MZ B cell equivalents, we evaluated our CD23- population for additional 
characteristics previously described for MZ populations. As seen in Figure 1B, CD86+ B 
cells were larger than CD86- B cells, indicative of more activated cells. While the 
 111 
proportion of CD86+ cells differed for individual tonsil samples (data not shown), 
indicating varying proportions of these cells in a resting and activated state, the 
proportion of CD86+ cells and their CD86 staining intensities were consistently higher 
for CD23- B cells than CD23+ B cells. Mouse MZ B cells also have been found to have 
high levels of CD86 (5). It has been suggested that these cells are in a constant state of 
activation due to their location between the lymphoid areas and venules, in close 
proximity to blood-borne antigens (5). 
 
Previous literature has described MZ B cells as first responders to pathogens due to 
their exposure to infection via blood or mucosal routes (22). Additionally, pathogen and 
vaccine adjuvant components may drain to lymph nodes and interact with MZ B cells 
(23). Consequently, it is relevant to determine the effect of PRR ligands on MZ B cell 
activation. The activation of tonsil CD23- B cells which contain MZ-like B cells by PRR 
ligands was measured by upregulation of CD86 expression. FACS-isolated CD23- B 
cells were stimulated overnight with the different PRR ligands. We noted that some 
samples of tonsil CD23- B cells had relatively high, pre-existing levels of CD86 
expression (Figure 1B). Following stimulation, R848, iE-DAP, and CpG moderately 
increased the percentage of CD86+ CD23- B cells (Figure 2).  In contrast, TDB 
decreased CD86 expression (Figure 2).  The compiled results for five different tonsil 
samples are provided in Figure 3.  Because of the sample-to-sample variation in CD86 
expression for unstimulated cultures (Figure 3A,B), results were normalized by 
calculating the stimulation ratios of PRR-stimulated cultures relative to unstimulated 
cultures (Figure 3B). Normalized data identified several statistically significant 
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differences between CD23- B cells stimulated with various PRR ligands (Figure 3D). Of 
note, R848-stimulated CD23- B cell CD86 expression was statistically different from 
CD23- B cells stimulated with GLA, iE-DAP, Poly (I:C), and TDB. Additionally, TDB-
stimulated CD23- B cells yielded the lowest frequency of CD86+ cells. While select PRR 
ligands may induce or maintain CD86 expression on CD23- B cells, others like TDB may 
suppress CD86 expression.  
 
MHC class II expression was examined as another potential indicator of B cell 
activation. PRR ligand-induced upregulation of MHC class II would represent an 
enhanced ability of B cells to present antigen to T helper cells. Upon isolation from tonsil 
tissue, CD23- B cells were characterized by high levels of MHC class II which were 
unaffected by PRR ligand stimulation (Figure 3E). It has been shown previously that 
human tonsillar B cells have increased expression of MHC class II following stimulation 
with TLR2, TLR7/8, and TLR9 ligands (24).  However, our results suggest that the 
CD23- B cell population from human tonsils already express a high level of MHC class II 
that is unaffected following PRR stimulation. 
 
3.2. The role of Notch in MZ development 
The Notch signaling pathway is important to the development, differentiation, 
proliferation and survival of mammalian cells (25). In mice, Notch2 signaling is of 
particular importance during the differentiation of transitional B cells into MZ B cells (26). 
Previously, we have shown that select PRR ligands can induce CD23 expression on 
transitional B cells, indicative of Fo maturation (Chapter 3). Transitional B cells 
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stimulated with R848 (TLR7/8 ligand) + IL4 were found to polarize toward a CD23+ Fo-
like phenotype, while transitional B cells stimulated with CpG (TLR9 ligand) alone 
polarized toward a CD23int/- T2/MZ-like phenotype (Chapter 3).   However, even for 
R848 + IL-4, a minority mature B cell population emerged which was CD23-.  We 
examined Notch signaling components by real-time qPCR in cultures stimulated under 
these two conditions. Notch signaling gene expression did not differentiate between B 
cell populations polarized toward CD23+ (Fo-like: R848+IL4 stimulated) versus CD23- 
(MZ-like: CpG stimulated) phenotypes (Figure 4A). This may have been due to the 
mixed phenotypes present in stimulated cultures.  Nevertheless, one of the genes 
consistently upregulated in both populations was NOTCH2NL (Figure 4B).  The 
NOTCH2NL gene product is a truncated form of Notch2 that has been implicated in the 
inhibition of Notch signaling (27). Induction of NOTCH2NL transcription by PRR 
stimulation may drive transitional B cells to mature via a Notch-independent pathway.   
 
In mice, following Notch2 receptor engagement, the active segment of Notch2 is 
cleaved and migrates to the nucleus where it binds to the DNA binding protein RBP-J, 
thus, driving transitional B cell to differentiate into MZ B cells (25, 28). When MINT, a 
negative regulator or Notch/RBP-J signaling is expressed, it competes for RBP-J 
binding thereby causing transitional B cells to differentiate into Fo B cells (26). A human 
homolog of MINT, SPEN, has been identified and may influence the differentiation of 
human transitional B cells (29). We examined the expression of SPEN in our study and 
did not observe upregulation of this gene in maturing human B cells (Figure 4A), 
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suggesting that the alternative NOTCH2NL inhibitor may replace SPEN as a negative 
regulator of Notch in human transitional B cell development.   
 
While the interplay of PRR ligands and Notch signaling in B cells has not been reported, 
several groups have examined the interaction of TLRs and Notch signaling in 
macrophages (25, 30). Macrophages stimulated with TLR ligands were found to 
upregulate the expression of Notch target genes, indicating cooperation between both 
pathways. Moreover, cytokines have the ability of modulating this process. Hu et al. 
found that IFNJ inhibited Notch target gene expression by directly affecting the Notch 
signaling pathway. Our results raise the possibility that transitional B cell exposure to 
stimulatory PRR ligands in the presence of IL-4, which like IFNJ utilizes the Jak/STAT 
pathway, inhibits MZ B cell differentiation in favor of FO B cell differentiation through 
down-regulation of Notch signaling.  
 
3.3. Mature B cell genes are downregulated following stimulation with TLR7/8 and TLR9 
ligands 
Since there were no clear differences in the expression of Notch signaling pathway 
genes using the various PRR ligand stimulating conditions, despite the distinct 
phenotypes resulting from these stimuli (Figure 6A), we decided to examine the 
expression of other genes associated with B cell development. The E protein pathway 
has been found to play a key role in B cell differentiation. BTK, Id2, Id3, Asb2, and 
TCF3/E47 are E protein pathway genes expressed differentially by MZ and Fo B cells in 
the mouse (31).  Higher levels of expression of Id2 and Asb2 have been reported for 
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mouse MZ B cells and higher Id3 levels are found in mouse Fo B cells, suggesting that 
these genes may be differentially expressed in human MZ and Fo B cells and play a 
role in this cell fate determination. To test this hypothesis, FACS-sorted human tonsil 
MZ-like B cells (CD3- CD19+ CD23- CD21+/- IgM+) and Fo B cells (CD3- CD19+ CD23+ 
CD21+/- IgD+) were evaluated for expression of B cell differentiation genes (Figure 4C). 
Consistent with the mouse data, MZ-like B cells expressed higher levels of Id2, Asb2, 
and TCF3, while Fo B cells expressed higher levels of BTK and Id3 (Figure 4C).  
 
To determine if TLR7/8 and TLR9 ligands drive transitional B cells to express any of 
these B cell maturation genes, transcripts were analyzed 12 hours post-stimulation with 
R848 + IL-4 or CpG alone (Figure 4C). In three replicate experiments, all five genes 
were down regulated in response to TLR7/8 + IL-4 and TLR9 ligation as compared to IL-
4 control B cells at this time point (data not shown). However, the degree of 
downregulation differed between cultures stimulated with R848 + IL-4 and CpG alone. 
Expression ratios were analyzed to determine the relative gene expression of CpG-
stimulated as compared to R848 + IL-4-stimulated transitional B cells.  CpG-stimulated 
cultures expressed slightly higher levels of Asb2 and TCF3 than R848 + IL-4 stimulated 
cultures, resembling the tonsil MZ-like B cells, and R848 + IL-4 stimulated cultures 
expressed more BTK than CpG-stimulated cultures, resembling the tonsil Fo-like B cells 
(Figure 4C). Unexpectedly, Id2, which is expressed at higher levels in MZ B cells in the 
mouse, was downregulated in CpG-stimulated cultures. Instead, CpG-stimulated 
cultures had elevated levels of Id3. This suggests that expression of Id2 and Id3 may 
not be expressed in the same manner by human as reported for murine mature B cells. 
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3.4. FcRL4 as a marker for tonsil MZ-like B cells 
Human MZ B cell equivalents have been shown to express surface IgM, CD27 and 
contain mutated IgV genes, properties generally associated with memory B cells (5). 
Due to these similarities between human MZ B cells and memory B cells, controversy 
exists over whether human MZ B cells are a subset of memory B cells, develop from 
memory B cells, or are a separate mature B cell population (17, 32).  
 
While CD21 expression is used as a marker of MZ B cells in mice (7), it is expressed by 
a proportion of both Fo and MZ human B cells (33-35) and therefore cannot be used as 
a specific indicator of human MZ B cell differentiation. FcRL4 (also known as IRTA1) is 
selectively expressed on a B cell subset located in the tonsil equivalent of the splenic 
marginal zone (36). We evaluated surface FcRL4 expression in tonsil B cells to confirm 
its utility in discriminating MZ B cells from other B cell populations, and in transitional B 
cell cultures as a marker for in vitro maturation of CD23- B cells with a MZ-like 
phenotype.  
 
Human B cell FcRL4 expression was initially examined using tonsillar B cells. 
Approximately 12% of CD3- CD19+ CD23- IgM+ B cells from the tonsil were found to 
express FcRL4 (Figure 5). This population was enriched for IgM+ IgD+ cells (>75%), 
characteristic of human tonsil naïve MZ equivalents (12). This is in comparison to the 
CD23+ IgM+ IgD+ human tonsil Fo B cell population which was mostly (98%) FcRL4 
negative (Figure 5). Therefore, we hypothesized that FcRL4 expression may allow for 
better identification of a MZ-like population. Previous studies suggest that MZ B cell 
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development requires commensal microbiota (37), which contain intrinsic PRR ligands. 
Additionally, it has been shown that patients deficient in TLR signaling molecules have a 
diminished IgM+ IgD+ CD27+ MZ-like B cell compartment (38), indicative of the role 
TLRs, and possibly other PRRs, play in MZ-like B cell development. Therefore, we 
stimulated transitional B cells with select PRR ligands, to determine whether PRR 
ligands have the potential to induce MZ-like B cell differentiation defined as R123lo/- 
CD23- IgM+ FcRL4+. Upon initiation of culture, less than 1% of transitional B cells are 
FcRL4+ (Figure 6B). When transitional B cells were stimulated with IL-4 alone or IL-4 
along with most PRR ligands, between 5-15% of CD19+ R123lo CD23- IgM+ cells 
acquired the FcRL4+ phenotype (Figure 6C). There was a trend for the highest increase 
in FcRL4+ cells in cultures stimulated with TDB + IL-4, although this difference was not 
statistically significant.  The induction of FcRL4 expression in cultured transitional B 
cells supports the interpretation that these cells may be differentiating into MZ-like B 
cells.  However, because stimulation with PRR ligands + IL-4 did not induce more 
FcRL4 expression than IL-4 alone, PRR signaling may not be a critical factor for MZ B 
cell maturation, in contrast to our observations on Fo B cell maturation (Chapter 3). It is 
also possible that other tissue-specific signals and cellular interactions may be required 
to enhance FcRL4 expression by MZ-like B cells. 
 
3.5. MZ B cell controversy 
Recent literature has demonstrated that human MZ B cells have variable surface 
marker expression and tissue distribution. It is therefore recognized that the human MZ 
B cell population is heterogeneous but shares three common characteristics: 1) the 
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ability to recirculate, 2) CD27 expression, and 3) the presence of mutated VDJ genes 
(39-41). Since these three characteristics are hallmarks of memory B cells, there has 
been a debate over whether MZ B cells are a subset of memory B cells or represent an 
independent B cell lineage. This controversy has been reviewed in Chapter 1. 
 
Briefly, utilizing paired blood and tissue samples Aranburu et al. (17) found three types 
of IgM memory B cells which indicates that the MZ may change with age consisting of 
innate IgM memory B cells at infancy and GC-experienced IgM memory B cells during 
adulthood. Therefore, depending on the source and individual’s age, the heterogeneous 
nature of the MZ B cell population may be reflected in transcriptome data.  
 
3.6. Human tonsil MZ-like B cell transcriptome 
In light of the controversy over whether marginal zone B cells correspond to a separate 
B cell lineage or a component of the IgM memory B cell population., several groups 
have studied the transcriptomes of murine and human B cell populations with marginal 
zone-like characteristics (42, 43). Kleiman et al. (43) identified murine splenic MZ B 
cells as B220+ IgMhi CD21hi IgD- CD23- CD24int CD9+ and compared the transcriptome 
to four other splenic B cell subsets. Transcriptional analysis revealed that this murine 
splenic MZ B cell population is enriched for genes that positively regulate NF-kB and 
control innate immune sensing molecules. Interestingly, a follicular B cell subset (FO-II) 
shared similar transcriptome expression of innate-like genes with the MZ B cell 
population, providing support for a plasticity between these populations (44). Descatoire 
et al. (42) identified human splenic MZ B cells as CD19+ IgM+ IgD+ CD27+ CD24+ 
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CD38lo and compared its transcriptome to splenic naïve B cells. Microarray analysis 
revealed that human splenic MZ B cells express select MZ-specific genes related to 
Notch signaling (DTX1) and transcriptional regulation (SOX7), as well as non-specific 
markers (CD27, CD300A, TNFSFR13B/TACI). These investigators also identified a 
subpopulation within naïve B cells that more closely resembled MZ B cells than the rest 
of the naïve B cell population, suggesting that these cells corresponded to MZ B cell 
precursors.  However, this transcriptome data were from individuals of various ages and 
we now know that the human marginal zone population is heterogenous and variable 
with age (17) 
Therefore, we decided to analyze the transcriptome of human tonsil MZ equivalents of 
children.  Based on previous literature characterizing the phenotype of tonsil MZ B cell 
equivalents (12, 36),  tonsil CD19+ CD23- IgM+ FcRL4+ MZ B cells were isolated by flow 
cytometry and their gene expression was compared to tonsil CD19+ CD23+ IgD+ Fo B 
cells. Using AmpliSeq technology, 20,000 unique human transcripts were queried, and 
counts were compared between CD23- IgM+ FcRL4+ and CD23+ IgD+ B cell subsets. 
More genes (194 genes) were upregulated in CD19+ CD23- IgM+ FcRL4+ MZ-like B cells 
as compared to Fo B cells (106 genes) (Figure 7A). The top 10 upregulated and 
downregulated genes are shown in Figure 7B. Among the highly upregulated genes in 
MZ B cells were the FCGR2C gene (Fc Fragment of the IgG receptor 
gene/pseudogene) and TNFSF11 (TNF superfamily member 11 (RANKL)).  Although 
initially described as a pseudogene, FCGR2C has multiple alleles, some of which 
encode functional gene products (45) that bind to IgG-antigen immune complexes and 
initiate either inhibitory of activating responses (46) and are associated with 
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susceptibility to infectious diseases. TNFSF11/RANKL RANKL has been shown to be 
produced by switched (CD27+ IgD-) and unswitched (CD27+ IgD+) memory B cells, the 
latter potentially also containing MZ B cells (47). CCR1 was upregulated in isolated MZ-
like B cells consistent with reports of CCR1 expression on tonsil intraepithelial B cells 
and lymphocytes in the mantle and marginal zones of follicles in the spleen (48). 
SIGLEC6 upregulation has not previously been noted in tonsil MZ B cells. However, 
previous work has shown that Siglec-6, a sialic acid-binding immunoglobulin like lectin, 
is almost exclusively expressed on peripheral B cells and moderately expressed in 
spleen tissues (48) indicating its importance for peripheral human B cells, which may 
include circulating splenic marginal zone B cells. 
 
A distinct set of highly differentially expressed genes for Fo B cells were SPRY1 
(Sprouts RTK Signaling Antagonist 1), ADAM23 (metallopeptidase), FCER2 gene 
encoding CD23, and S1PR1 (sphingosine-1-phosphate receptor 1 (Figure 7).  SPRY1, 
a regulator of receptor tyrosine kinase signaling, has been shown to be involved in the 
regulation of CD4+ and CD8+ effector responses through its effect on TCR signaling (49) 
and may serve a similar function in BCR signaling. S1PR1 has been shown to be 
upregulated in B cells that have reached the mature follicular state (50) and may be 
required for egress of naïve B cell from lymphoid tissue back into circulation.  
 
The MZ-like tonsil B cell population used in our study was highly enriched for FcRL4. 
Previous gene expression analysis comparing FcRL4+ and FcRL4- tonsil B cell 
populations revealed similar expression profiles to our FACS-isolated tonsil MZ B cells 
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(51). Ehrhardt et al. identified TNFSF11 (RANKL), RUNX2, and SOX5 as FcRL4+ B cell 
genes because they are expressed exclusively on FcRL4+ tonsil B cells as compared to 
FcRL4- tonsil B cells and other peripheral B cell subsets. Similarly, we observed 
increased TNFSF11 (RANKL) expression (fold change: -4.4; p-value: <0.001) and 
RUNX2 (fold change: -2.45; p-value: <0.001) (Figure 7). In addition to the FcRL4+ 
specific gene expression profiles, AICDA and DUSP4 are upregulated in our MZ-like B 
cells (Figure 7), similar to previous literature (51).  
 
Ingenuity Pathway Analysis comparing tonsil Fo and MZ-like B cell profiles showed 
differential gene expression in IL-4 signaling, Notch signaling, PI3K signaling, BCR 
signaling, cell cycle regulators, Th1/Th2 activation markers, IL-6 signaling, NF-kB 
signaling, and Protein Kinase A signaling pathways (Figure 8A-C). Genes involved in 
BCR signaling and responsible for Th1/Th2 activation were primarily upregulated in MZ 
B cells. Alternatively, most genes involved in PI3K signaling were upregulated in Fo B 
cells. Other signaling pathways like IL-4, IL-6, and NF-kB have differential expression of 
select genes within the pathway indicating that resting Fo and MZ B cells utilize different 
genes in the same pathways. These differences may be due to cell-specific metabolism 
related to Fo B cells being a resting population until encountering antigen and MZ B 
cells being an activated B cell subset. 
 
Our transcriptome analysis identified several genes associated with a mature tonsil MZ-
like B cell population, including RUNX2 and CD27. To determine whether our in vitro 
cultures induced gene expression similar to our mature MZ-like B cell population, we 
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isolated RNA from transitional B cells stimulated with CpG + IL-4 or CpG alone. FCER2 
(CD23) was analyzed as a positive control as our previous data showed that CpG + IL-4 
induces high CD23 expression (CD23+: Fo-like) and CpG alone induces little to no 
CD23 expression (CD23-: MZ-like) (Chapter 3). We observed an increase in FCER2 
expression in CpG + IL-4 stimulated transitional B cells and a decrease in CpG alone 
stimulated transitional B cells, in agreement with our protein expression data in Chapter 
3 (Figure 9). While RUNX2 expression was down-regulated in transitional B cells 
stimulated with CpG + IL-4, we expected to see an increase in RUNX2 expression in 
transitional B cells stimulated with CpG alone. We did not observe any RUNX2 
expression in CpG-stimulated cultures in our analyses. CD27 was upregulated in both 
stimulation conditions indicating that both of our in vitro culture conditions drove some 
cells to differentiate into either memory or MZ-like populations. 
 
4. Discussion 
Human MZ B cells are a controversial B cell subset whose phenotype and 
transcriptome are still under evaluation. The purpose of this study was to evaluate the 
phenotype of the human tonsil CD23- B cell population with respect to MZ-like B cell 
characteristics and to identify other cell surface markers and genes specific to human 
tonsil CD23- IgM+ FcRL4+ MZ-like B cells. Development of a panel of genes that are 
highly upregulated in MZ B cells and that clearly distinguish them from the rest of the 
naïve B cell population should enable clearer assessment of the developing MZ-like B 
cell population in vitro upon stimulation with various PRR ligands. 
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The first part of this study evaluated the phenotype, activation status, and gene 
expression of the CD23+ and CD23- B cell populations. As described in Chapter 3, 
human tonsil CD23+ B cells displayed a Fo-like phenotype (CD21+ IgDhi IgM+  
CD38lo/-). In comparison, human tonsil CD23- B cells represented a more 
heterogeneous population, although further analysis of the CD23- IgD+ B cells 
subpopulation displayed a MZ-like phenotype (CD21+ IgM+ CD38lo/-). Therefore, we 
were interested in further characterizing the MZ-like equivalents within the tonsil CD23- 
B cell population. We found that the CD23- B cell population expressed high levels of 
CD86 and MHC class II prior to PRR ligand stimulation. Following R848 and CpG 
stimulation of the CD23- B cell population increased the frequency of CD86+ cells. TDB 
decreased the frequency of CD86+ CD23- cells. Following PRR ligand stimulation, the 
CD23- B cell population retained MHC class II expression, regardless of PRR stimulus. 
These results supported previous reports that the MZ B cell compartment is in a state of 
constant activation (5). However, the frequency of CD86+ CD23- B cells may be 
modified depending on the PRR ligand stimulus. 
 
Notch signaling and B cell-specific maturation genes have been described in the mouse 
and human model during MZ-like B cell differentiation (42, 52-56). Our results did not 
find an overall enhancement of Notch signaling genes in cultures stimulated CpG (MZ 
polarizing) versus R848 + IL-4 (Fo-polarizing).  However, we were able to demonstrated 
that NOTCH2NL, a Notch2 inhibitor, showed a trend of upregulation in transitional B 
cells in response to both MX- and Fo-polarizing stimuli (TLR7/8 + IL-4 and TLR9). We 
suspected that the presence of mixed populations following TLR7/8 + IL-4 and TLR9 
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stimulation may have confounded the gene expression results. Follow-up studies 
utilizing more highly purified CD23- IgM+ IgD+ tonsil B cells may provide more clear-cut 
data. B cell-specific maturation genes involved in the E protein pathway (BTK, ID2, ID3, 
ASB2, TCF3) were expressed in our mature tonsil Fo and MZ-like B cells, in 
accordance with murine B cell gene expression. Following in vitro stimulation of 
transitional B cells with R848 + IL-4 or CpG alone, we found that the relative gene 
expression of BTK, ASB2, and TCF3 corresponded with mature Fo and MZ B cells in 
the mouse and human.  
 
The second part of this study evaluated whether FcRL4 may be a useful marker to 
identify MZ-like B cells. The absence of CD23 was useful in isolating a tonsil population 
containing MZ-like B cells, while FcRL4 was shown to be useful in identifying CD23-IgD+ 
IgM+ naïve MZ-like B cells within this CD23- B cell population. We attempted to use 
FcRL4 as a marker of MZ-like B cell differentiation from cord blood transitional B cells in 
vitro. While transitional B cells were mostly FcRL4-negative, 5-15% of cultured B cells 
acquired FcRL4 expression after stimulation, which suggests that IL-4 and select PRR 
ligands may support MZ-like differentiation. However, additional studies are needed to 
determine if more optimal conditions can be developed to further enhance FcRL4 
expression by developing MZ B cells. As an alternative to CD21 and FcRL4 expression, 
several groups have used CD27 as a marker to identify MZ B cells (16, 42, 57-59). It 
was also noted in gene expression studies that one of the highly upregulated genes for 
the FcRL4 population was CD27, suggesting that CD27 and FcRL4 are both expressed 
in these MZ-like B cells. Conventionally, CD27 has been associated with somatically-
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hypermutated memory B cells. Recently, CD27+ IgD+ IgM+ and CD27+ IgD- IgM+ B cells 
have been found and characterized in the human splenic marginal zone (34), tonsils 
and gut-associated lymphoid tissue (16) and many have hypothesized that MZ B cells 
are a subset of memory B cells. This hypothesis is very controversial and has been 
reviewed elsewhere (17, 32, 57) and discussed in Chapter 1. CD27 expression in the 
marginal zone of human spleens does not occur in children younger than two years old 
(60). From six days to five months of age, most B cells are naïve and IgD-positive. 
Additionally, this period is associated with an increase in CD27-expressing B cells in the 
marginal zone. Previous work has shown that CD27-positive B cells are densely located 
at the follicular periphery, however centrocytes, centroblasts, and plasma cells from 
these tissues also express CD27 (58). Therefore, although not pursued in this study, 
CD27 may be useful in identifying MZ B cell equivalents in humans, but only in 
combination with other markers depending on the tissue of origin. MZ B cells in humans 
may correspond to a heterogeneous population, with several different phenotypes 
depending on the individual’s age and the tissue in which MZ B cells are located (16, 
17).  
 
The final part of this study evaluated and compared the transcriptomes of human tonsil 
CD23- IgM+ FcRL4+ MZ-like B cells and CD23+ IgD+ Fo B cells. The origin of MZ B cells 
as a subset of memory B cells or as a distinct lineage arising from transitional B cells or 
naïve B cells has been disputed. While the origin of MZ B cells remains unclear, there is 
mounting evidence that the MZ compartment is composed of a heterogeneous 
population of B cells that is age- and tissue-dependent (16, 17, 32). Comparison of the 
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transcriptome profiles of human tonsil FO and MZ-like B cells allowed for further 
characterization of these cells. CD23- IgM+ FcRL4+ MZ-like B cells were enriched for 
IgD+ cells, indicative of a naïve MZ-like B cell population. Our transcriptome analysis 
identified several genes specific to human tonsil naïve MZ-like B cells including RUNX2, 
TBX21, CD27, TNFSF11 (RANKL), and SOX5. CD27, RANKL, RUNX2, and SOX5 
have been associated with MZ-like B cells in previous studies (51), while the association 
of TBX21/Tbet with MZ B cells is a novel finding.  Gene expression of transitional B 
cells induced to mature in vitro by PRR ligand stimuli has been performed for a few of 
these genes (RUNX2, CD27) and analysis of additional genes are in progress.  
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Figure 1. Characterization of tonsil B cells. Histogram plots showing CD21, CD23, 
IgD, IgM, and CD38 expression of FACS-isolated tonsil CD3- CD19+ B cells gated on 
CD23+ B cells and CD23- B cells, and CD23- IgD+ B cells. Isotype control (blue 
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Figure 2. Representative data showing CD86 expression following PRR 
stimulation with R848, GLA, iE-DAP, Poly (I:C), TDB, and CpG. MZ B cells were 
FACS-isolated from human tonsil tissue and cultured overnight with PRR ligands. CD86 
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Figure 3. Marginal zone B cell activation following PRR stimulation as measured 
by CD86 and MHC class II. % CD86+ MZ B cells following PRR stimulation in five 
individuals (A). Summarized data showing CD86+ frequency (B) and CD86 mean 
fluorescence intensity (MFI) (C) following overnight culture with PRR ligands. 
Stimulation ratios of % CD86+ relative to unstimulated control (D). Representative data 




 Stimulation  
 Unstimulated R848 GLA iEDAP Poly (I:C) TDB CpG 
Exp 1 28.7% 44.5% 32.8% 34.5% 29.9% - 38.6% 
Exp 2 44.3% 76.4% 45.5% 54.4% 43.9% 14.7% 60.9% 
Exp 3 32.3% 46.4% 30.4% 36.9% 28.5% 10.5% 38.9% 
Exp 4 6.95% 13.2% 9.73% 11.1% 6.68% 2.75% 17.8% 









































Figure 4. Gene expression analysis of transitional B cells stimulated with  
R848 + IL4 and CpG alone. Transitional B cells stimulated with IL4 alone, R848 + IL4, 
and CpG alone were collected 12 hours post-stimulation. RNA was extracted and 
converted to cDNA for qPCR analysis on Notch Signaling PrimePCR plates. Gene 
expression fold change is expressed relative to IL4 alone cultures (A). NOTCH2NL 
expression of transitional B cells stimulated with R848 + IL4 or CpG alone, relative to 
IL4 alone cultures (B). B cell maturation gene (BTK, ID2, ID3, ASB2, TCF3) expression 
on tonsil MZ relative to Fo B cells. Human cord blood transitional B cells stimulated with 
CpG (MZ-like induction) relative to R848 + IL4 (Fo-like induction) (C). Data are 



























































































Figure 5. Characterization of FcRL4+ tonsil B cells. CD23/CD21 plots show that only 
36% of CD23- cells are IgM+, with a fraction of those being FcRL4+. The majority (77%) 
of CD23- IgM+ FcRL4+ tonsil B cells are also IgD+, indicative of a naïve population. Most 









CD23+ IgD+ FcRL4+ B cells










































Figure 6. FcRL4 expression following PRR stimulation. Following two-day culture 
with PRR ligands, cells were gated on single, viable, R123-, CD23-, IgM+ cells (A). 
CD19+ R123hi CD24+ CD38+ 






Representative baseline FcRL4 expression on CD19+ R123hi CD24+ CD38+ cord blood 
transitional B cells (B). Representative data (C) and bar graph (D) summarizing % 
















Figure 7. Transcriptome analysis of tonsil follicular B cells and marginal zone B 
cells. Mean differences plot (top) showing the gene expression fold change. Statistically 
significant differences in gene expression between tonsil follicular B cells and marginal 
zone B cells are in red. The top upregulated and downregulated genes in tonsil follicular 





















Figure 8. Pathway analysis of tonsil follicular B cells and marginal zone B cells. 
Heatmap display of tonsil follicular (three left columns) and marginal zone (three right 
columns) B cell populations from three individuals. Pathways analyzed were IL-4 
signaling, Notch signaling, PI3K signaling in B lymphocytes (A); BCR signaling, Cyclins 
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signaling, PI3K signaling in B lymphocytes (A); BCR signaling, Cyclins & cell cycle 
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Figure 9. Transitional B cell gene expression following 48h stimulation with  
CpG + IL-4 or CpG alone. FCER2 (CD23), RUNX2, and CD27 gene expression were 


























Vaccines are considered one of the most effective public health interventions for the 
control of infectious diseases (1). While many highly effective vaccines exist, new and 
improved vaccines for the prevention of infectious diseases of major public health 
concern are still necessary (2). The addition of adjuvants has helped to improve the 
immunogenicity and efficacy of vaccines (3-7). Specifically, PRR ligands are being 
incorporated as vaccine adjuvants due to their immunostimulatory potential (8-10). 
Several vaccines in experimental and clinical use utilize PRR ligands alone or in 
combination with other commonly used vaccine adjuvants (4, 10). Examples of FDA-
approved vaccines containing PRR ligands include: SHINGRIX and HEPLISAV-B. 
SHINGRIX is indicated for the prevention of herpes zoster reactivation in individuals 
older than 50 years of age (11). SHINGRIX contains varicella zoster glycoprotein E and 
AS01B, a liposomal adjuvant including MPL (TLR4 ligand) and QS-21 (saponin). 
HEPLISAV-B is an FDA-approved vaccine for the prevention of hepatitis B in adults 18 
years of age and older (12). The HEPLISAV-B vaccine contains CpG 1018 as its 
adjuvant. HEPLISAV-B is the first FDA-approved vaccine whose adjuvant is composed 
of a PRR ligand alone. The previously approved hepatitis B vaccine for use in children 
and adults utilizes alum as its adjuvant. 
 
PRR ligands may activate many immune cell types including dendritic cells, monocytes, 
and B cells (13-17). While the effects of several PRR ligands have been tested on 
dendritic cells and monocytes in the mouse and human (18), the direct effect of PRR 
ligands on human B cells is unclear and understudied. More specifically, there is little to 
no literature defining the direct role of PRR ligands on human B cell maturation and 
 150 
activation. In contrast to alum, a commonly utilized vaccine adjuvant, PRR ligands have 
defined receptors and signaling pathways. As such, the incorporation of PRR ligands as 
vaccine adjuvants will allow for more specific and defined responses that may involve 
direct effects on B cell subpopulations.  
 
In humans, transitional B cells are a prominent B cell subset during infancy and early 
childhood (birth – 4 years of age) (19). Additionally, this developmental period coincides 
with the time routine vaccinations are being administered. It is reasonable to 
hypothesize that vaccines containing PRR ligands as adjuvants may affect the mature B 
cell compartment by driving the maturation of transitional B cells. Select PRR ligand-
induced changes in the mature B cell compartment, due to direct effects on the 
maturation of transitional B cells, may guide rational vaccine adjuvant design in the 
future.  
 
The overall goal of this work was to determine whether PRR ligands could induce B cell 
maturation from transitional to mature naïve B cells in humans. Additionally, do different 
PRR ligands influence the follicular (Fo) or marginal zone (MZ) B cell fate decision? If 
so, how can we measure these effects? We hypothesized that PRR ligands can drive B 
cell maturation from the transitional B cell stage and that select PRR ligands are 




Human transitional B cells can be identified using several surface markers including 
CD24 and CD38. Previous literature relied primarily on high CD24 and CD38 
expression, however, some late stage transitional B cells express low levels of CD24 
and CD38 (20, 21). Recently, the lack of ABCB1 expression has been associated with 
the transitional B cell subset (22) while mature, naïve B cells are characterized as 
expressing ABCB1. Rhodamine 123 (R123) is a cell-permeable, fluorescent dye that is 
excreted via the ABCB1 transporter. Therefore, transitional B cells retain high levels of 
R123. We utilized the expression of several cell surface markers and R123 
fluorescence to isolate transitional B cells from human cord blood. Additionally, high 
CD23 expression and R123 extrusion were indicative of transitional B cell maturation 
into naïve B cells.  
 
Our studies confirmed previous work that IL-4 was necessary for transitional B cell 
survival. After two days of culture, IL-4-supplemented transitional B cell cultures 
contained a small population of CD23hi follicular-like B cells. The highest frequency of 
CD23hi Fo-like B cells were produced in transitional B cell cultures stimulated with R848, 
iE-DAP, and CpG in the presence of IL-4. In contrast, transitional B cells stimulated with 
TDB plus IL-4 or CpG alone resulted in little to no increase in CD23hi Fo-like B cells. 
Rather the majority of these cells expressed intermediate levels of CD23 while a 
minority were CD23- CD21+ B cells. These CD23- CD21+ B cells bore a phenotypic 
resemblance to MZ-like B cells (23). Previous literature has shown that CpG (TLR9 
ligand) drove human transitional B cells to develop into IgM memory B cells, a CD27+ 
subset similar to the MZ population (24). While our study does not confirm the 
 152 
transitional B cell development into IgM memory B cells or MZ-like B cells, we observed 
the emergence of a small CD23- CD21+ population which may have contained these 
cells. 
 
As mentioned above, in addition to CD23 acquisition B cell maturation can also be 
assessed by ABCB1 expression as measured by R123 extrusion.   In a separate set of 
experiments, we used a combination of surface antigen expression and R123 
fluorescence to characterize transitional B cell maturation.  This allowed us to 
reconstruct a pattern of B cell maturation induced by stimulation with IL-4 and IL-4 plus 
R848 as illustrated below (Figure 1).   
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Figure 1. Pattern of transitional B cell maturation induced by either IL-4 or IL-4 + 
R848. R123 retention is indicated by dark green (R123hi), light green (R123int), and no 
green (R123neg). Majority populations are indicated by dark blue arrows. Minority 








































           CD21+ 
            CD23var 
         IgDhi 







































































Three populations of B cells were observed following IL-4 or IL-4 + R848 stimulation, 
with R123 high (R123hi) cells corresponding to immature, transitional B cells, R123 
intermediate to low (R123lo) cells corresponding to maturing B cells, and R123 negative 
(R123neg) cells corresponding to fully mature, naïve B cells. In cultures receiving either 
stimuli, residual R123hi transitional B cells already acquired CD23 on their surface and 
expressed high levels of IgM, indicating that transitional B cells become CD23 positive 
and upregulate surface IgM prior to expressing ABCB1. R123neg, mature B cells 
recovered from stimulated cultures were heterogeneous in surface phenotype, 
consisting of a majority population of CD23hi IgMhi IgDvar B cells and minority populations 
of CD23- IgM+ IgD+ B cells and CD23- IgM- IgD- B cells. The CD23hi IgMhi IgDvar 
phenotype corresponds to that of naïve, Fo B cells. The CD23- IgM+ IgD+ population 
resembles MZ B cells which may be derived directly from transitional B cells or from 
CD23+ precursors in the naïve B cell population.  While CD23 expression is generally 
considered a marker of human follicular B cells, it is also found on human splenic MZ 
precursors (25). It is interesting to note that previous literature has supported the 
capacity of Fo B cells to develop into MZ precursors (26). In summary, stimulation of 
transitional B cells with IL-4 and IL-4 + R848 appears to result in a mixed population of 
late-stage transitional B cells, Fo B cells, and MZ-like precursors.  However, the 
representation of these populations may be dependent on the nature of the stimuli, as 
IL-4 was less effective at generating fully-mature B cells than IL-4 and R848 in 
combination. In our study transitional B cells stimulated with R848/CpG + IL-4 induced a 
CD23+ follicular-like polarizing condition with a minority population of CD23- MZ-like B 
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cells, while transitional B cells stimulated with CpG alone remain mostly CD23- and 
resemble MZ-like B-cells  
Previous literature has demonstrated that murine Fo and MZ B cells can be identified by 
genes related to Notch signaling and several genes associated with B cell maturation in 
the mouse (BTK, ID2, ID3, ASB2, TCF3) (27-31). Notch signaling plays a key role in the 
cell fate decision of transitional B cells into mature Fo or MZ B cells (32, 33). While 
Notch signaling inhibits Fo B cell development, it is a necessary signaling pathway in 
MZ B cell development. When we measured gene expression of cells from our follicular-
like polarizing condition as compared to cells from our marginal zone-like polarizing 
condition, we saw variable expression of several Notch-related genes. However, 
NOTCH2NL, a truncated form of NOTCH2 with inhibitory properties (34), is consistently 
upregulated in both Fo-like and MZ-like polarizing conditions. The elevated expression 
of NOTCH2NL suggests that transitional B cells stimulated with PRR ligands are 
differentiating in a NOTCH-independent manner.  
 
In addition to NOTCH-related genes, we evaluated genes known to be associated with 
murine follicular B cells (BTK, ID3) and marginal zone B cells (ID2, ASB2, TCF3). We 
confirmed gene expression in purified human tonsil follicular and marginal zone B cells. 
We observed that transitional B cells under our Fo-like polarizing condition express 
BTK, similar to human tonsil follicular B cells. We observed that transitional B cells 
under our MZ-like polarizing condition express ASB2 and TCF3.  These gene 
expression data in combination with surface phenotype and ABCB1 data suggest that 
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PRR stimulation, in the presence of IL-4, can drive the maturation of translational B cells 
into fully mature, naïve B cells. 
 
Previous literature has demonstrated the difficulty in defining mature human marginal 
zone B cells by cell surface phenotype due to the heterogeneity within the population 
based on tissue location (35-38). Analyses of tonsil MZ-like B cells and B cells that 
reside in tonsillar MZ-like regions have shown that FcRL4 is expressed on these cells 
(39-42). A subset of our CD23- IgM+ B cells expressed FcRL4 (Chapter 4), similar to 
previously described tonsillar MZ-like B cells. Therefore, for the remaining studies we 
decided to utilize the CD23- IgM+ FcRL4+ phenotype to define the MZ-like population. 
Additionally, we evaluated whether IL-4 and PRR ligands have the capacity to induce 
FcRL4 expression in maturing transitional B cells. While the starting transitional B cell 
population was uniformly FcRL4 negative, a percentage of these cells acquired FcRL4 
expression when cultured with IL-4 + TDB. TDB + IL-4 promoted non-follicular B cell 
development (Chapter 3) and increased FcRL4 cells (Chapter 4) which together indicate 
that TDB + IL-4 may promote maturation of transitional B cells to the MZ phenotype. In 
culture conditions with other PRR ligands, it may be possible to further increase FcRL4 
expression by providing additional tissue signals, such as Notch-signaling pathway 
interactions. 
 
To enable us to reliably identify marginal zone B cells and distinguish them from 
transitional B cells and follicular B cells in our in vitro cultures, we set out to identify 
genes uniquely related to R123hi CD24+ CD38+ human transitional B cells, CD23+ IgD+ 
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human tonsil follicular B cells, and CD23- IgM+ FcRL4+ human tonsil marginal zone-like 
B cells using RNASeq analysis. We found that transitional B cells were more 
transcriptionally active compared to follicular B cells. Additionally, pathway analysis 
identified many differentially expressed genes that were uniquely expressed in either 
the Fo or MZ subset. We analyzed FCER2 gene expression as a positive control since 
FCER2 encodes for CD23, one of the differentially expressed markers we used to sort 
Fo and MZ-like subsets. RT-PCR analysis confirmed that CD23+ IgD+ Fo B cells 
express ADAM28, BATF, RUNX1 and TNFRSF17, while CD23- IgM+ FcRL4+ tonsil 
MZ-like B cells express CD27, RUNX2, TBX21. Preliminary analysis evaluating in vitro 
maturation of transitional B cells stimulated with CpG and CpG + IL-4 indicated an 
increased expression of the Fo-B cell associated FCER2/CD23 gene in cultures 
stimulated with CpG + IL-4 and a down-regulation of this gene in cultures stimulated 
with CpG alone.  Furthermore, RUNX2, a probable MZ-specific gene, was down-
regulated in cultures stimulated with CpG + IL-4.  These results confirm our phenotypic 
analyses suggested that CpG favored the development of MZ-like B cells while CpG + 
IL-4 promoted the development of Fo-like B cells.  Additional studies to confirm this 
observation with a larger panel of genes associated with these two B cell subsets are in 
progress. Importantly, the pattern of gene expression observed in this study supports 
our conclusion that a subpopulation of transitional B cells can be induced to mature into 
both Fo-like and MZ-like B cells under specific stimulation conditions. 
 
To the best of our knowledge, this is the first study to look at the effect of several PRR 
ligands on the maturation of human transitional B cells into mature, naïve B cells and to 
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examine the follicular versus marginal zone B cell fate decision. The PRR ligands we 
chose to investigate have been incorporated in experimental and clinical vaccines as 
adjuvants. Therefore, this study is highly relevant for the rational design of future 
vaccine adjuvants.  
 
In support of our original hypothesis for Specific Aim 1, we found the TLR7/8, NOD1, 
Mincle, and TLR9 ligands have the most pronounced effect on transitional B cell 
maturation.  In addition to influencing the development of Fo B cells and MZ B cells, 
these PRR ligands may also determine whether the antibody response induced will 
favor the development of long-lived plasma cells or short-lived plasma cells, 
respectively. 
 
Figure 2. Summary of the effect of select PRR ligands on the early childhood B 
cell compartment and its influence on the resulting immune response. 
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Therefore, vaccines with adjuvants that include TLR7/8, NOD1, Mincle, or TLR9 ligands 
may alter the B cell compartment through their influence on transitional B cell 
maturation in the very young. The rational design of vaccine adjuvants that take into 
consideration the effect of PRR ligands on B cell maturation and differentiation may 
improve the immunogenicity and efficacy of childhood vaccines.  
 
In support of our original hypothesis for Specific Aim 2, we identified several mature Fo 
and MZ-like B cell-specific genes. These genes may allow for more accurate 
identification of human Fo and MZ-like subsets, which may be difficult to identify by 
surface phenotype alone. Furthermore, these differentially expressed genes may allow 
us to distinguish B cells that are maturing along the Fo or MZ pathway at the gene 
expression level. The assessment of B cell subset gene expression following 




The results of this study have led to several future directions for our research. While this 
study looked at selected PRR ligands, it would be interesting to examine the effects of 
the well-known vaccine adjuvant (alum) and newer immunostimulatory molecules 
(STING ligands and bacterial toxins) on transitional B cell maturation. By assessing the 
ability of these compounds to drive transitional B cell maturation, we can elucidate the 
direct effect of various current and potential vaccine adjuvants on human B cells. 
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This study found that select PRR ligands have the capacity to drive transitional B cell 
maturation. In addition to driving transitional B cell maturation, PRR ligands have been 
implicated in the removal of autoreactive B cells from the mature repertoire. Specifically, 
in the absence of TLR signaling molecules, more autoreactive B cells are found in the 
mature B cell pool. We hypothesize that other PRR ligands may play a role in removing 
autoreactive B cells. One approach to test this hypothesis would be to compare the 
immunoglobulin repertoire in B cells prior to and following stimulation with a panel of 
PRR ligands. 
 
Our in vitro system allows us to analyze the direct effects of PRR ligands on human 
transitional B cells. While this is necessary to understand phenotypic and genetic 
changes in direct response to stimuli, PRR ligand stimulation may have indirect effects 
on transitional B cell maturation as well. To learn more about these indirect effects, an 
in vivo system is necessary. Below we propose two approaches for the in vivo analysis 
of B cell subsets. 
 
Three-dimensional (3D) cell culture systems have become popular in recent years due 
to their increased relevance to in vivo systems. In a traditional two-dimensional (2D) cell 
culture system, a monolayer of cells from a cell suspension is seeded on a flat surface 
like a tissue culture plate or petri dish. This method allows for equal access to nutrients 
and even culture conditions. However, cells do not exist as 2D monolayers in vivo. As 
compared to traditional 2D monolayer cell cultures, 3D cell culture systems allow for 
appropriate cell structure and communication between different cell types. To date, 3D 
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culture systems have been used to investigate many biological questions including 
tumor biology, drug resistance/susceptibility, immune response to infection, cell toxicity 
and hair growth. Previous 3D culture systems have included single cells suspended in 
agarose or gelatin, organoid structures using scaffolding nanoparticles, and lymphoid 
tissue sections on gelatin rafts. By isolating human lymphoid tissue for 3D culture, we 
can examine changes in cell subset frequency in response to PRR stimulation or 
vaccine formulations containing antigen and adjuvant. 
 
Another approach would be to examine the effect of different vaccine/adjuvant 
formulations as a result of vaccination. There are currently two licensed vaccines for 
Hepatitis B. The first formulation to be licensed includes Hepatitis B surface antigen and 
alum. While more than 90% of the population responds to this formulation, there is a 
small group of low responders. In response to this low responding population, a second 
Hepatitis B vaccine formulation was developed containing Hepatitis B surface antigen 
and CpG (TLR9 ligand). To directly compare the effect of alum and CpG on the 
transitional B cell population and mature B cell subpopulations, one could compare the 
frequency of B cell subpopulations in adults who received HepB-alum and adults who 
received HepB-CpG. This study should be conducted in both a cross-sectional and 
longitudinal manner. Additionally, since others have noted B cell compartment 
differences between children and adults. It will be useful to also examine the transitional 
and mature B cell subpopulations in children before and after routine vaccination with 
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